<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" dtd-version="1.3" xml:lang="EN" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//ACS//DTD ACS Journal DTD v1.02 20061031//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName ACSJournal-v102.dtd?><?SourceDTD.Version 1.02?><?ConverterInfo.XSLTName acs2nlmx2.xsl?><?ConverterInfo.Version 1?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">ACS Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">ACS Infect Dis</journal-id><journal-id journal-id-type="publisher-id">id</journal-id><journal-id journal-id-type="coden">aidcbc</journal-id><journal-title-group><journal-title>ACS Infectious Diseases</journal-title></journal-title-group><issn pub-type="epub">2373-8227</issn><publisher><publisher-name>American Chemical Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">8922275</article-id><article-id pub-id-type="pmid">35143160</article-id><article-id pub-id-type="doi">10.1021/acsinfecdis.1c00643</article-id><article-categories><subj-group><subject>Article</subject></subj-group></article-categories><title-group><article-title>DNA-Dependent Binding of Nargenicin to DnaE1 Inhibits
Replication in <italic>Mycobacterium tuberculosis</italic></article-title></title-group><contrib-group><contrib contrib-type="author" id="ath1"><name><surname>Chengalroyen</surname><given-names>Melissa D.</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="notes-6" ref-type="notes">&#x02207;</xref></contrib><contrib contrib-type="author" id="ath2"><name><surname>Mason</surname><given-names>Mandy K.</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="notes-6" ref-type="notes">&#x02207;</xref></contrib><contrib contrib-type="author" id="ath3"><name><surname>Borsellini</surname><given-names>Alessandro</given-names></name><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" id="ath4"><name><surname>Tassoni</surname><given-names>Raffaella</given-names></name><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" id="ath5"><name><surname>Abrahams</surname><given-names>Garth L.</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="aff3" ref-type="aff">&#x000a7;</xref><xref rid="notes-5" ref-type="notes">#</xref></contrib><contrib contrib-type="author" id="ath6"><name><surname>Lynch</surname><given-names>Sasha</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath7"><name><surname>Ahn</surname><given-names>Yong-Mo</given-names></name><xref rid="aff3" ref-type="aff">&#x000a7;</xref></contrib><contrib contrib-type="author" id="ath8"><name><surname>Ambler</surname><given-names>Jon</given-names></name><xref rid="aff4" ref-type="aff">&#x02225;</xref></contrib><contrib contrib-type="author" id="ath9"><name><surname>Young</surname><given-names>Katherine</given-names></name><xref rid="aff5" ref-type="aff">&#x022a5;</xref></contrib><contrib contrib-type="author" id="ath10"><name><surname>Crowley</surname><given-names>Brendan M.</given-names></name><xref rid="aff6" ref-type="aff">&#x025bc;</xref></contrib><contrib contrib-type="author" id="ath11"><name><surname>Olsen</surname><given-names>David B.</given-names></name><xref rid="aff5" ref-type="aff">&#x022a5;</xref></contrib><contrib contrib-type="author" id="ath12"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4146-0930</contrib-id><name><surname>Warner</surname><given-names>Digby F.</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath13"><name><surname>Barry III</surname><given-names>Clifton E.</given-names></name><xref rid="aff3" ref-type="aff">&#x000a7;</xref></contrib><contrib contrib-type="author" id="ath14"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4333-206X</contrib-id><name><surname>Boshoff</surname><given-names>Helena I. M.</given-names></name><xref rid="aff3" ref-type="aff">&#x000a7;</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath15"><name><surname>Lamers</surname><given-names>Meindert H.</given-names></name><xref rid="cor1" ref-type="other">*</xref><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath16"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4824-9115</contrib-id><name><surname>Mizrahi</surname><given-names>Valerie</given-names></name><xref rid="cor2" ref-type="other">*</xref><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><aff id="aff1"><label>&#x02020;</label>SAMRC/NHLS/UCT
Molecular Mycobacteriology Research Unit, DST/NRF Centre of Excellence
for Biomedical TB Research, Institute of Infectious Disease and Molecular
Medicine and Department of Pathology, Faculty of Health Sciences, <institution>University of Cape Town</institution>, Anzio Road, Observatory 7925, <country>South Africa</country></aff><aff id="aff2"><label>&#x02021;</label>Cell
and Chemical Biology, <institution>Leiden University
Medical Center</institution>, Einthovenweg 20, 2333 ZC Leiden, <country>The Netherlands</country></aff><aff id="aff3"><label>&#x000a7;</label>Tuberculosis
Research Section, Laboratory of Clinical Immunology and Microbiology, <institution>National Institute of Allergy and Infectious Disease,
National Institutes of Health</institution>, 9000 Rockville Pike, Bethesda, Maryland 20892, <country>United
States</country></aff><aff id="aff4"><label>&#x02225;</label>Wellcome
Centre for Infectious Diseases Research in Africa, <institution>University of Cape Town</institution>, Anzio Road, Observatory 7925, <country>South Africa</country></aff><aff id="aff5"><label>&#x022a5;</label>Infectious
Disease, <institution>Merck &#x00026; Co. Inc.</institution>, West Point, Pennsylvania 19446, <country>United States</country></aff><aff id="aff6"><label>&#x025bc;</label>Discovery
Chemistry, <institution>Merck &#x00026; Co. Inc.</institution>, West Point, Pennsylvania 19446, <country>United States</country></aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Email: <email>m.h.lamers@lumc.nl</email>.</corresp><corresp id="cor2"><label>*</label>Email: <email>valerie.mizrahi@uct.ac.za</email>.</corresp></author-notes><pub-date pub-type="epub"><day>10</day><month>02</month><year>2022</year></pub-date><pub-date pub-type="ppub"><day>11</day><month>03</month><year>2022</year></pub-date><volume>8</volume><issue>3</issue><fpage>612</fpage><lpage>625</lpage><history><date date-type="received"><day>09</day><month>12</month><year>2021</year></date></history><permissions><copyright-statement>&#x000a9; 2022 The Authors. Published by American Chemical Society</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>The Authors</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p content-type="toc-graphic"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="id1c00643_0007" id="ab-tgr1"/></p><p>Natural products
provide a rich source of potential antimicrobials
for treating infectious diseases for which drug resistance has emerged.
Foremost among these diseases is tuberculosis. Assessment of the antimycobacterial
activity of nargenicin, a natural product that targets the replicative
DNA polymerase of <italic>Staphylococcus aureus</italic>, revealed that it is a bactericidal genotoxin that induces a DNA
damage response in <italic>Mycobacterium tuberculosis</italic> (<italic>Mtb</italic>) and inhibits growth by blocking the replicative
DNA polymerase, DnaE1. Cryo-electron microscopy revealed that binding
of nargenicin to <italic>Mtb</italic> DnaE1 requires the DNA substrate
such that nargenicin is wedged between the terminal base pair and
the polymerase and occupies the position of both the incoming nucleotide
and templating base. Comparative analysis across three bacterial species
suggests that the activity of nargenicin is partly attributable to
the DNA binding affinity of the replicative polymerase. This work
has laid the foundation for target-led drug discovery efforts focused
on <italic>Mtb</italic> DnaE1.</p></abstract><kwd-group><kwd>antimicrobial drug discovery</kwd><kwd>Mycobacterium tuberculosis</kwd><kwd>DnaE1</kwd><kwd>DNA damage</kwd><kwd>DNA polymerase</kwd><kwd>nargenicin</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution>Howard Hughes Medical Institute</institution><institution-id institution-id-type="doi">10.13039/100000011</institution-id></institution-wrap></funding-source><award-id>55007649</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution>Crick African Network</institution><institution-id institution-id-type="doi">NA</institution-id></institution-wrap></funding-source><award-id>African Career Accelerator Award</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution>Ernest Oppenheimer Memorial Trust</institution><institution-id institution-id-type="doi">10.13039/501100009978</institution-id></institution-wrap></funding-source><award-id>Harry Oppenheimer Fellowship</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution>South African Agency for Science and Technology Advancement</institution><institution-id institution-id-type="doi">10.13039/501100006312</institution-id></institution-wrap></funding-source><award-id>DSI/NRF Centre of Excellence for Biomedical TB Res</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution>South African Medical Research Council</institution><institution-id institution-id-type="doi">10.13039/501100001322</institution-id></institution-wrap></funding-source><award-id>Extramural Research Unit</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution>Broad Institute</institution><institution-id institution-id-type="doi">10.13039/100013114</institution-id></institution-wrap></funding-source><award-id>Turning the Tide Against Tuberculosis</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution>Division of Intramural Research, National Institute of Allergy and Infectious Diseases</institution><institution-id institution-id-type="doi">10.13039/100006492</institution-id></institution-wrap></funding-source><award-id>NA</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution>Bill and Melinda Gates Foundation</institution><institution-id institution-id-type="doi">10.13039/100000865</institution-id></institution-wrap></funding-source><award-id>OPP1158806</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution>Bill and Melinda Gates Foundation</institution><institution-id institution-id-type="doi">10.13039/100000865</institution-id></institution-wrap></funding-source><award-id>INV-004757</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution>Bill and Melinda Gates Foundation</institution><institution-id institution-id-type="doi">10.13039/100000865</institution-id></institution-wrap></funding-source><award-id>INV-002474</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>id1c00643</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>id1c00643</meta-value></custom-meta><custom-meta><meta-name>ccc-price</meta-name><meta-value/></custom-meta></custom-meta-group></article-meta></front><body><p id="sec1">Claiming
an estimated 1.5 million
lives in 2020, tuberculosis (TB) remains one of the leading causes
of death globally from an infectious disease.<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> The severe disruptions to health services wrought by the COVID-19
pandemic are predicted to worsen this grim toll by a further 1 million
TB deaths per annum over the next four years.<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> In the absence of a highly efficacious vaccine, prolonged chemotherapy
with combinations of anti-TB drugs forms the cornerstone of TB control.
However, the increase of drug resistance through ongoing evolution
and spread of drug-resistant strains of the etiologic agent, <italic>Mycobacterium tuberculosis</italic> (<italic>Mtb</italic>),
is undermining current efforts. This problem, exacerbated by additional
treatment delays caused by the pandemic, underscores the urgent need
for new TB drugs with distinct mechanisms of action for inclusion
in shorter, safer, and more effective drug regimens. The TB drug discovery
and development pipeline established in recent years has begun to
deliver new and repurposed drugs and combinations that have revolutionized
the treatment of drug-resistant TB<sup><xref ref-type="bibr" rid="ref2">2</xref></sup> and
demonstrated that treatment shortening is an achievable goal.<sup><xref ref-type="bibr" rid="ref3">3</xref></sup> However, maintaining this momentum requires replenishment
of the pipeline with high-quality hit compounds that show mechanistic
novelty.<sup><xref ref-type="bibr" rid="ref4">4</xref></sup> This is a key objective of the
Tuberculosis Drug Accelerator (TBDA).<sup><xref ref-type="bibr" rid="ref5">5</xref></sup></p><p>Of the vital cellular processes targeted by TB drugs in clinical
use, DNA replication stands out as relatively under-represented;<sup><xref ref-type="bibr" rid="ref6">6</xref>&#x02212;<xref ref-type="bibr" rid="ref8">8</xref></sup> this is despite the high vulnerability of some genes essential for
DNA replication in <italic>Mtb</italic>,<sup><xref ref-type="bibr" rid="ref9">9</xref></sup> including those encoding DNA gyrase, the target of the fluoroquinolones,
moxifloxacin, gatifloxacin, and levofloxacin, and the only DNA metabolic
enzyme currently targeted for TB therapy. Fluoroquinolones inhibit
DNA gyrase with bactericidal consequences for <italic>Mtb</italic>(<xref ref-type="bibr" rid="ref10">10</xref>,<xref ref-type="bibr" rid="ref11">11</xref>) and have been incorporated in second-line therapy
for multidrug-resistant (MDR) TB<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> and
in treatment-shortening regimens for drug-susceptible TB.<sup><xref ref-type="bibr" rid="ref3">3</xref></sup> The identification of novel scaffolds that target
DNA gyrase remains an active area of investigation,<sup><xref ref-type="bibr" rid="ref13">13</xref>,<xref ref-type="bibr" rid="ref14">14</xref></sup> while topoisomerase I is also being pursued as a new TB drug target.<sup><xref ref-type="bibr" rid="ref15">15</xref></sup> Recently, the replisome&#x02014;the macromolecular
machine that copies the bacterial chromosome&#x02014;has emerged as
an attractive target for TB<sup><xref ref-type="bibr" rid="ref6">6</xref>,<xref ref-type="bibr" rid="ref7">7</xref></sup> and antibacterial drug
discovery, more generally.<sup><xref ref-type="bibr" rid="ref16">16</xref></sup> Key discoveries
involving natural products have added impetus to exploring this target
further: first, griselimycin, a cyclic depsipeptide discovered more
than 50 years ago, was shown to bind with high affinity and selectivity
to the &#x003b2;-clamp (DnaN) at the site of interaction with DNA polymerase
and other DNA metabolizing enzymes.<sup><xref ref-type="bibr" rid="ref17">17</xref></sup> During
DNA replication, the &#x003b2;-clamp interacts with DnaE1, the replicative
DNA polymerase termed variously as DnaE, DnaE1, or PolC in different
bacteria, greatly enhancing the processivity of the polymerase. Griselimycin
interferes with the protein interaction between DnaE1 and the &#x003b2;-clamp,
affecting the processivity of DNA replication.<sup><xref ref-type="bibr" rid="ref17">17</xref></sup> The mechanistic novelty of griselimycin led to the development
of the analogue, cyclohexyl-griselimycin, which has improved potency
and stability and demonstrated comparable efficacy to rifampicin when
used in combination with first-line drugs in a mouse infection model.<sup><xref ref-type="bibr" rid="ref17">17</xref></sup> Second, studies in <italic>Staphylococcus
aureus</italic> identified the replicative DNA polymerase,
DnaE, as the target of nargenicin A1 (referred to here as nargenicin),<sup><xref ref-type="bibr" rid="ref18">18</xref></sup> which belongs to a class of partially saturated
alicyclic polyketides comprising an octalin ring (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>A).<sup><xref ref-type="bibr" rid="ref19">19</xref></sup> Nargenicin is an ether-bridged macrolide antibiotic first isolated
from various <italic>Nocardia</italic> species almost three decades
ago.<sup><xref ref-type="bibr" rid="ref20">20</xref>,<xref ref-type="bibr" rid="ref21">21</xref></sup> It is a narrow-spectrum antimicrobial<sup><xref ref-type="bibr" rid="ref18">18</xref></sup> with activity against gram-positive bacteria,
including methicillin-resistant <italic>S. aureus</italic> and <italic>Micrococcus luteus</italic>.<sup><xref ref-type="bibr" rid="ref22">22</xref></sup> The identification of <italic>narR/ngnU</italic>,<sup><xref ref-type="bibr" rid="ref21">21</xref>,<xref ref-type="bibr" rid="ref23">23</xref></sup> a <italic>dnaE</italic> homologue immediately
adjacent to the nargenicin biosynthetic gene cluster in the producer
organism, <italic>Nocardia</italic> sp. CS682,<sup><xref ref-type="bibr" rid="ref24">24</xref></sup> suggested a mechanism of self-resistance to nargenicin
using NarR/NgnU as a &#x0201c;decoy&#x0201d;.<sup><xref ref-type="bibr" rid="ref21">21</xref></sup></p><fig id="fig1" position="float"><label>Figure 1</label><caption><p>Antimycobacterial
activity profile of nargenicin. (A) Chemical
structure of nargenicin A1. (B) Antibacterial activity (minimal inhibitory
concentration, MIC) of nargenicin (NRG) in mycobacteria and other
organisms illustrating the effect of media composition on activity.
7H9, Middlebrook 7H9 media; GAST/(Fe), glycerol-alanine-salts (with
iron); Glu, glucose; (O)ADC, (oleic acid)-albumin-dextrose-catalase;
Tw, Tween-80; Tx, Tyloxapol. (C) Time&#x02013;kill kinetics of nargenicin
in <italic>Mtb</italic>, measured by CFU enumeration. Error bars represent
the SD derived from two biological replicates. Ciprofloxacin (CIP;
MIC = 1.5 &#x003bc;M) was used as a comparator. (D) Drug-induced lytic
activity measured by the release of GFP from <italic>Mtb</italic> H37Rv-GFP
at the indicated concentrations.<sup><xref ref-type="bibr" rid="ref32">32</xref></sup> Linezolid
(LIN; MIC = 1.5 &#x003bc;M) and meropenem (MERO; MIC = 5.2 &#x003bc;M)
were used as the nonlytic and lytic controls, respectively. Data are
representative of the two biological replicates.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="id1c00643_0002" id="gr1" position="float"/></fig><p>The potent bactericidal activity and low frequency of resistance
for nargenicin in <italic>S. aureus</italic>(<xref ref-type="bibr" rid="ref18">18</xref>) led us to investigate the antimycobacterial
properties of this molecule<sup><xref ref-type="bibr" rid="ref25">25</xref></sup> under the
auspices of the TBDA. Here, we show that nargenicin is a bactericidal
genotoxin that induces a DNA damage response in <italic>Mtb</italic> that is accompanied by cellular elongation and potential weakening
of the cell envelope. We further demonstrate that the antimycobacterial
activity of nargenicin is mediated through the inhibition of DNA synthesis,
consistent with the inhibition of the DNA polymerase activity of purified
DnaE1. Structural analysis by cryo-electron microscopy (cryo-EM) revealed
a unique mode of binding by nargenicin to <italic>Mtb</italic> DnaE1
in the presence of DNA in which nargenicin occupies the position of
both the incoming nucleotide and templating base and stacks onto the
terminal base pair. We show that the antibacterial efficacy of nargenicin
as a DNA replication inhibitor is attributable, at least in part,
to the DNA binding affinity of the organism&#x02019;s replicative polymerase.</p><sec id="sec2"><title>Results</title><sec id="sec2.1"><title>Nargenicin
is Bactericidal against <italic>Mtb In Vitro</italic></title><p>Nargenicin
was shown to have a minimum inhibitory concentration
(MIC) of 12.5 &#x003bc;M against <italic>Mtb</italic> H37Rv under standard
culture conditions (7H9/OADC/Tw) (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>B; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.1c00643/suppl_file/id1c00643_si_001.pdf">Table S1</ext-link>).
In this culture medium, nargenicin showed comparable activity against
a range of drug-sensitive and drug-resistant clinical isolates of <italic>Mtb</italic> and was active against <italic>Mycobacterium
smegmatis</italic> (<italic>Msm</italic>). The activity against <italic>Mtb</italic> diminished significantly when Tween-80 was replaced
by Tyloxapol to disperse the mycobacteria. A synergistic effect of
Tween-80 has been observed for other TB drugs, most notably rifampicin<sup><xref ref-type="bibr" rid="ref26">26</xref></sup> and streptomycin.<sup><xref ref-type="bibr" rid="ref27">27</xref></sup> The differential potency of nargenicin in media containing Tween-80 <italic>versus</italic> Tyloxapol likely reflects the differential impact
of these two detergents on the lipid composition of the cell envelope
at the concentrations typically used for clump dispersal<sup><xref ref-type="bibr" rid="ref28">28</xref></sup> with Tween-80 increasing permeability to the
drug.<sup><xref ref-type="bibr" rid="ref29">29</xref>,<xref ref-type="bibr" rid="ref30">30</xref></sup> Nargenicin also showed increased potency
in GAST/(Fe)/Tween-80. The <italic>in vitro</italic> selectivity index
was reasonable with limited cytotoxicity against the HepG2 cell line
(CC50 &#x0003e; 100 &#x003bc;M).</p><p>Time&#x02013;kill kinetic analysis
revealed
that nargenicin was bactericidal in <italic>Mtb</italic> H37Rv, showing
time-dependent kill with limited dose-dependency over the concentration
range tested (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>C). To ascertain whether this bactericidal activity was accompanied
by cell lysis, we quantified green fluorescent protein (GFP) release
from H37Rv-GFP.<sup><xref ref-type="bibr" rid="ref31">31</xref>,<xref ref-type="bibr" rid="ref32">32</xref></sup> Nargenicin treatment led to GFP
release from day 4 onwards, peaking on days 6&#x02013;7 (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>D). Griselimycin treatment
also resulted in delayed GFP release analogous to that elicited by
nargenicin, but no release of GFP was observed upon exposure to the
DNA gyrase inhibitors, ciprofloxacin, or moxifloxacin, demonstrating
that the GFP release was not a generic consequence of disrupting DNA
metabolism (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>D).</p></sec><sec id="sec2.2"><title>Nargenicin Inhibits DNA Synthesis and is Genotoxic in <italic>Mtb</italic></title><p>To ascertain whether nargenicin shares the
same mechanism of action in mycobacteria as in <italic>S. aureus</italic>,<sup><xref ref-type="bibr" rid="ref18">18</xref></sup> we applied a suite of complementary
biological profiling assays in <italic>Mtb</italic> and <italic>Msm</italic>. Multiple attempts to isolate spontaneous nargenicin-resistant mutants
in <italic>Mtb</italic> or <italic>Msm</italic> by plating 10<sup>9</sup>&#x02013;10<sup>10</sup> bacilli on media containing nargenicin
at 5&#x02013;20&#x000d7; MIC (<italic>Mtb</italic>) or 1&#x02013;10&#x000d7;
MIC (<italic>Msm</italic>) were unsuccessful, yielding no heritably
resistant mutants. Reasoning that nargenicin would elicit a DNA damage
response if it disrupts DNA replication, we used the <italic>Mtb</italic> P<italic>recA</italic>-LUX reporter strain to monitor the activity
of the DNA-damage-inducible <italic>recA</italic> promoter in response
to drug treatment.<sup><xref ref-type="bibr" rid="ref33">33</xref></sup> Like fluoroquinolones
and griselimycin, nargenicin triggered dose-dependent induction of
luminescence (<xref rid="fig2" ref-type="fig">Figures <xref rid="fig2" ref-type="fig">2</xref></xref>A and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.1c00643/suppl_file/id1c00643_si_001.pdf">S1</ext-link>). Comparative DNA microarray
analysis revealed a transcriptomic signature for nargenicin-treated <italic>Mtb</italic> that shared key features with those elicited by mitomycin
C and fluoroquinolones (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.1c00643/suppl_file/id1c00643_si_001.pdf">Figures S2A, S2B, and Table S2</ext-link>).<sup><xref ref-type="bibr" rid="ref34">34</xref>,<xref ref-type="bibr" rid="ref35">35</xref></sup> Genome-wide transcriptome analysis
by RNA-seq revealed a profound upregulation of <italic>dnaE2</italic>, <italic>imuA</italic>&#x02032;, and <italic>imuB</italic>, components
of the mycobacterial &#x0201c;mutasome&#x0201d; responsible for DNA
damage tolerance and damage-induced mutagenesis<sup><xref ref-type="bibr" rid="ref35">35</xref>,<xref ref-type="bibr" rid="ref36">36</xref></sup> and other DNA repair and recombination genes, including <italic>recA</italic>, <italic>radA</italic>, <italic>uvrA</italic>, <italic>lhr</italic>, and <italic>adnAB</italic> (<xref rid="fig2" ref-type="fig">Figures <xref rid="fig2" ref-type="fig">2</xref></xref>B, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.1c00643/suppl_file/id1c00643_si_001.pdf">S2C</ext-link>, and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.1c00643/suppl_file/id1c00643_si_002.xlsx">Data S1</ext-link>), which are contained in the PafBC regulon.<sup><xref ref-type="bibr" rid="ref37">37</xref></sup> Interestingly, deletion of either <italic>recA</italic>(<xref ref-type="bibr" rid="ref38">38</xref>) or <italic>dnaE2</italic>(<xref ref-type="bibr" rid="ref35">35</xref>,<xref ref-type="bibr" rid="ref36">36</xref>) had a negligible impact on the antimycobacterial activity of nargenicin
(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.1c00643/suppl_file/id1c00643_si_001.pdf">Table S1</ext-link>). Genes most highly downregulated
by nargenicin were enriched in those associated with cell division
(<italic>ftsZ</italic>, <italic>whiB2</italic>, and <italic>ripA</italic>) and included genes involved in cell envelope biogenesis (<italic>e.g</italic>., <italic>fbpC</italic>) (<xref rid="fig2" ref-type="fig">Figures <xref rid="fig2" ref-type="fig">2</xref></xref>B and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.1c00643/suppl_file/id1c00643_si_001.pdf">S2C</ext-link>).</p><fig id="fig2" position="float"><label>Figure 2</label><caption><p>Nargenicin
is a genotoxin that inhibits DNA replication in mycobacteria.
(A) Analysis of <italic>recA</italic> promoter activity elicited by
nargenicin using the reporter strain, PrecA-LUX.<sup><xref ref-type="bibr" rid="ref33">33</xref></sup> Ciprofloxacin (CIP, 2&#x000d7; MIC) was a positive control.
RLU, relative luminescence units. (B) Volcano plot illustrating the
transcriptional response (RNA-seq) of <italic>Mtb</italic> to nargenicin
(10&#x000d7; MIC). Differential expression (Log&#x0202f;2 fold-change)
of nargenicin-treated cultures versus dimethyl sulfoxide (DMSO)-treated
controls are plotted against adjusted P-values (<italic>P</italic>-value) for each gene, indicating a significant upregulation of genes
involved in the response of <italic>Mtb</italic> to DNA-damaging agents.<sup><xref ref-type="bibr" rid="ref35">35</xref></sup> (C) Morphological profiling of <italic>Msm</italic> in response to treatment with nargenicin illustrates that bacillary
morphotypes<sup><xref ref-type="bibr" rid="ref39">39</xref></sup> cluster in UMAP space with
those of CRISPRi hypomorphs in genes involved in DNA replication,
including <italic>dnaE1</italic>. Black circle, untreated; black square,
DMSO-treated; red circle, nargenicin-treated at 1&#x000d7; MIC; red square,
nargenicin-treated at 2&#x000d7; MIC; and red triangle, nargenicin-treated
4&#x000d7; MIC. (D) Selective inhibition of DNA synthesis by nargenicin
in <italic>Mtb</italic>. The incorporation of radiolabeled precursors
into the total nucleic acid (tNA), protein (Prot), peptidoglycan (PG),
and fatty acid (FA) was measured in the absence (DMSO) or presence
of nargenicin at 2&#x000d7; or 20&#x000d7; MIC (black and red bars, respectively).
The level of radiolabel incorporation into each macromolecular species
is depicted relative to the DMSO-treated control. Assay specificity
was confirmed using the following pathway-specific antibiotics as
positive controls: ofloxacin (DNA replication; 5 &#x003bc;g/mL), streptomycin
(protein synthesis; 10 &#x003bc;g/mL), <sc>d</sc>-cycloserine (peptidoglycan
biosynthesis; 5 &#x003bc;g/mL), and isoniazid (fatty acid biosynthesis;
0.2 &#x003bc;g/mL). Error bars represent the standard deviations from
two experimental repeats.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="id1c00643_0003" id="gr2" position="float"/></fig><p>Morphological profiling of <italic>Msm</italic> exposed to nargenicin
revealed a filamentation phenotype with the proportion of elongated
bacilli in the population increasing with the drug dose (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.1c00643/suppl_file/id1c00643_si_001.pdf">Figure S3</ext-link>). This drug-induced profile clustered
closely in UMAP space with those resulting from transcriptional silencing
of components of the DNA replication and repair machinery (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>C), as previously
defined,<sup><xref ref-type="bibr" rid="ref39">39</xref></sup> further implicating the disruption
of DNA metabolism in the mode of action of nargenicin. Direct evidence
for the inhibition of DNA replication was then obtained from a macromolecular
incorporation assay, which compares the incorporation of radiolabeled
precursors into the total nucleic acid, DNA, protein, peptidoglycan,
or fatty acid in cells treated with an experimental drug <italic>versus</italic> controls. Nargenicin had a profound effect on DNA synthesis resulting
in 60% and &#x0003e;95% reduction in [<sup>3</sup>H]-uracil incorporation
when used to treat <italic>Mtb</italic> at 2&#x000d7; and 20&#x000d7; MIC,
respectively. In contrast, nargenicin had a limited impact on RNA,
protein, peptidoglycan, and fatty acid synthesis (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>D). Together, these results
were consistent with the replicative polymerase, DnaE1, as the likely
target of nargenicin in mycobacteria.</p><p>To investigate this further,
we assessed the impact of modulating
the level of <italic>dnaE1</italic> expression on the susceptibility
of mycobacteria to nargenicin. We generated a set of fluorescently
labeled <italic>Mtb</italic> hypomorphs carrying inducible <italic>dnaE1</italic> CRISPR interference (CRISPRi)<sup><xref ref-type="bibr" rid="ref40">40</xref></sup> constructs and determined the inhibitory activity of nargenicin
against these strains in the presence or absence of the anhydrotetracycline
(ATc) inducer. Marked hypersensitization to nargenicin was observed
for all four hypomorphs under conditions of <italic>dnaE1</italic> silencing (+ATc) but not in the uninduced controls (-ATc) (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>A&#x02013;C). Importantly,
the effect was specific to nargenicin, as evidenced by the lack of
effect of <italic>dnaE1</italic> silencing on the susceptibility of <italic>Mtb</italic> to isoniazid or ciprofloxacin, which target mycolic
acid biosynthesis and DNA gyrase, respectively (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>C). Together, these results identified DnaE1
as a potential target of nargenicin in <italic>Mtb</italic>. Using
a vector shown previously to conditionally overexpress <italic>Msm</italic> DnaE1,<sup><xref ref-type="bibr" rid="ref41">41</xref></sup> we found that conditional overexpression
of <italic>Msm dnaE1</italic> in <italic>Msm</italic> or <italic>Mtb</italic>, as further confirmed by quantitative real-time polymerase chain
reaction (qRT-PCR) analysis (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.1c00643/suppl_file/id1c00643_si_001.pdf">Figure S4C</ext-link>), had no effect on the nargenicin susceptibility of either organism
(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.1c00643/suppl_file/id1c00643_si_001.pdf">Figure S4A,B</ext-link>). Therefore, the DnaE1 copy
number alone did not determine nargenicin efficacy in mycobacteria.</p><fig id="fig3" position="float"><label>Figure 3</label><caption><p>Transcriptional
silencing of <italic>dnaE1</italic> by inducible
CRISPRi selectively hypersensitizes <italic>Mtb</italic> to nargenicin.
(A) Location of sgRNAs 3, 6, 11, and 13 on the <italic>Mtb dnaE1</italic> gene (not drawn to scale). (B) <italic>In vitro</italic> growth
phenotypes of the four inducible CRISPRi hypomorphs in <italic>dnaE1</italic> constructed in a strain of <italic>Mtb</italic> carrying a constitutively
expressed mScarlet reporter. Strain growth was measured using a microplate
alamarBlue assay after 7 days&#x02019; exposure to ATc at a concentration
ranging from 0.1&#x02013;200 ng/mL. Columns highlighted in red represent
the IC<sub>50</sub> for ATc. Data plotted represent the average and
standard deviation of two technical replicates for one of the two
independent experiments. (C) The four <italic>dnaE1</italic> hypomorphs
were tested for susceptibility to nargenicin (NRG) alongside the control
drugs, ciprofloxacin (CIP) and isoniazid (INH). Drug-mediated growth
inhibition of the <italic>Mtb dnaE1</italic> mScarlet sgRNA 3 (black), <italic>Mtb dnaE1</italic> mScarlet 6 (green), <italic>Mtb dnaE1</italic> mScarlet sgRNA 11 (blue), <italic>Mtb dnaE1</italic> mScarlet sgRNA
13 (purple) hypomorphs and <italic>Mtb</italic> mScarlet vector control
(red) strains in the presence (+ATc, 100 ng/mL) or absence of an inducer
(-ATc) was determined by measuring fluorescence intensity at day 14.
Data represent the average and standard error of two technical replicates
for one representative experiment, fitted with a dose&#x02013;response
curve (nonlinear regression model). Experiments were performed in
triplicate.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="id1c00643_0004" id="gr3" position="float"/></fig></sec><sec id="sec2.3"><title>Nargenicin Differentially
Inhibits Bacterial Polymerases</title><p>Based on the microbiological
evidence, we investigated whether nargenicin
inhibited the DNA polymerase activity of <italic>Mtb</italic> DnaE1
in a biochemical assay. For comparison, we included <italic>S. aureus</italic> DnaE, as well as the extensively characterized
replicative DNA polymerase from <italic>Escherichia coli</italic>, DNA polymerase III &#x003b1; (Pol III&#x003b1;). To monitor the polymerase
activity, we used a real-time polymerase assay in which the incorporation
of dGMPs in the primer strand quenches the fluorescent signal of a
fluorescein group at the 5&#x02032; end of the template strand.<sup><xref ref-type="bibr" rid="ref41">41</xref></sup> We found that nargenicin also inhibits the activity
of <italic>Mtb</italic> DnaE1, albeit at &#x0223c;20-fold higher concentrations
than <italic>S. aureus</italic> DnaE (IC<sub>50</sub> = 125 and 6 nM, respectively) under the conditions of this assay
(<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>A). Surprisingly,
the <italic>E. coli</italic> polymerase was only significantly
inhibited by nargenicin at concentrations higher than 10 &#x003bc;M.</p><fig id="fig4" position="float"><label>Figure 4</label><caption><p>Mechanism
of DNA polymerase inhibition by nargenicin. (A) Nargenicin
inhibition curves of three bacterial replicative DNA polymerases, <italic>S. aureus</italic> DnaE (green line), <italic>Mtb</italic> DnaE1 (orange line), and <italic>E. coli</italic> Pol
III&#x003b1; (blue line), show IC<sub>50</sub> values of 8, 125, and
13&#x0202f;000 nM, respectively. (B) Cryo-EM structure of <italic>Mtb</italic> DnaE1 bound to DNA and nargenicin in yellow. (C) Close-up view of
the nargenicin molecule located between the displaced template base
and His787. Cryo-EM map is shown in a blue mesh. (D) Composite binding
site of nargenicin between the last base pair of the DNA duplex, the
displaced templated base, and the fingers domain of the polymerase.
(E) Top view of the binding site showing the &#x0201c;base pairing&#x0201d;
of nargenicin onto the last base pair of the DNA duplex (ssDNA overhang
not shown for clarity). (F) Nargenicin binding pocket in DnaE1 as
viewed from the DNA. All residues located with 5 &#x000c5; of nargenicin
are shown in green sticks. Hydrogen bonds between the protein and
nargenicin are indicated with black dashed lines.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="id1c00643_0005" id="gr4" position="float"/></fig></sec><sec id="sec2.4"><title>Cryo-EM Reveals Mechanism of Inhibition by Nargenicin</title><p>To
elucidate the mechanism of polymerase inhibition, we determined
the structure of full-length <italic>Mtb</italic> DnaE1 in complex
with nargenicin and a DNA substrate by cryo-EM (<xref rid="fig4" ref-type="fig">Figures <xref rid="fig4" ref-type="fig">4</xref></xref>B&#x02013;F and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.1c00643/suppl_file/id1c00643_si_001.pdf">S5</ext-link>). The structure was determined to a resolution of 2.9 &#x000c5; with
well-defined density for the polymerase active site, DNA, and the
bound nargenicin molecule (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>B&#x02013;F). The cryo-EM structure of <italic>Mtb</italic> DnaE1 is identical to the previously determined crystal structure<sup><xref ref-type="bibr" rid="ref42">42</xref></sup> with the exception of the oligonucleotide/oligosaccharide
binding (OB) domain that was not included in the crystal structure
(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.1c00643/suppl_file/id1c00643_si_001.pdf">Figure S6</ext-link>). The OB-domain is flexible
as it shows a weaker density in the cryo-EM map when compared to the
rest of the molecule (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.1c00643/suppl_file/id1c00643_si_001.pdf">Figures S5C and S6C</ext-link>). The flexibility of the OB-domain is consistent with cryo-EM structures
of <italic>E. coli</italic> Pol III&#x003b1; that show
a 70 &#x000c5; movement of the OB-domain between the DNA-bound and DNA-free
state.<sup><xref ref-type="bibr" rid="ref43">43</xref></sup></p><p>The DNA is bound in a canonical
manner between the thumb and fingers domains, as was previously observed
for other C-family DNA polymerases.<sup><xref ref-type="bibr" rid="ref43">43</xref>,<xref ref-type="bibr" rid="ref44">44</xref></sup> The nargenicin
molecule is bound in the polymerase active site and is sandwiched
between the last base pair of the DNA duplex, the first base of the
template strand, and the fingers domain of the polymerase (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>D). Nargenicin occupies
both the position of the incoming nucleotide as well as the template
base and thus mimics the position of the newly synthesized base pair
(<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>E). To do
so, the first unpaired template base is displaced from its position
and bumps into Pro668 of an adjacent helix (residues 668 to 673) that
becomes disordered. On the protein side, nargenicin occupies a shallow
pocket and only makes three direct contacts with the protein: Arg667
and His787 make a hydrogen bond to two oxygens in nargenicin, while
Gln638 makes a hydrogen bond with the nitrogen in the pyrrole ring
(<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>F). The opposite
end of nargenicin that is located on top of His787 makes no interaction
with the protein as its nearest neighbor is over 5 &#x000c5; away.</p><p>The binding of nargenicin is reminiscent of the binding of aphidicolin
in human DNA polymerase &#x003b1; (hPol&#x003b1;).<sup><xref ref-type="bibr" rid="ref45">45</xref></sup> Although the two inhibitors differ in the structure (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.1c00643/suppl_file/id1c00643_si_001.pdf">Figure S7A</ext-link>) and the polymerases belong to different
families (hPol&#x003b1; is a B-family polymerase, whereas <italic>Mtb</italic> DnaE1 a C-family polymerase), both inhibitors are bound between
the last base pair of the DNA and the polymerase fingers domain, occupy
the position of both incoming and templating base, and displace the
templating base (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.1c00643/suppl_file/id1c00643_si_001.pdf">Figure S7B,C</ext-link>). However,
owing to the structural differences in the polymerase active sites,
it is unlikely that nargenicin can inhibit the human polymerase as
modeling of nargenicin into the hPol&#x003b1; structure reveals several
clashes with the protein (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.1c00643/suppl_file/id1c00643_si_001.pdf">Figure S7D</ext-link>).
The similar mechanism of action of the two inhibitors is derived from
different organisms&#x02014;aphidicolin is derived from the mold, <italic>Cephalosporium aphidicola</italic>,<sup><xref ref-type="bibr" rid="ref45">45</xref></sup> whereas nargenicin is produced by a <italic>Nocardia</italic> species<sup><xref ref-type="bibr" rid="ref19">19</xref>,<xref ref-type="bibr" rid="ref20">20</xref></sup>&#x02014;provides a remarkable example of convergent evolution.</p></sec><sec id="sec2.5"><title>Drug Resistance through Allostery</title><p>The structure described
above shows that the DNA forms a crucial part of the nargenicin binding
site, consistent with the previous observation that binding of nargenicin
to <italic>S. aureus</italic> DnaE only occurs in the
presence of DNA.<sup><xref ref-type="bibr" rid="ref18">18</xref></sup> This DNA dependency
of binding may also hold the key to the differences in inhibition
between <italic>S. aureus</italic> DnaE, <italic>Mtb</italic> DnaE1, and <italic>E. coli</italic> Pol III&#x003b1;
(<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>). The predicted
nargenicin binding sites for <italic>S. aureus</italic> DnaE and <italic>E. coli</italic> Pol III&#x003b1; are
highly similar to those of <italic>Mtb</italic> DnaE1 (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>A,B), and the three residues
that make a hydrogen bond with nargenicin are conserved in all three
species. Hence, the difference in sensitivity does not appear to have
its origin in the binding site. Moreover, a mutation in <italic>S. aureus</italic> DnaE (a serine to leucine mutation at position
765, equivalent to <italic>Mtb</italic> DnaE1 residue 860) that renders
it resistant to nargenicin is located &#x0223c;30 &#x000c5; away from
nargenicin (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>C). This mutation is immediately adjacent to the region of the fingers
domain that interacts with the phosphate backbone of the double-stranded
DNA substrate. Therefore, we hypothesized that the potency of nargenicin
to inhibit a DNA polymerase may be dictated by the polymerase&#x02019;s
affinity for DNA. To test this, we measured the DNA affinity of the
three polymerases by fluorescence anisotropy using a primed DNA substrate
(<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>D). The three
DNA polymerases show strikingly different dissociation constants of
&#x0223c;6 nM for <italic>S. aureus</italic> DnaE, 250
nM for <italic>Mtb</italic> DnaE1, and 12 &#x003bc;M for <italic>E. coli</italic> Pol III&#x003b1;. Importantly, these DNA affinities
correlate with the relative sensitivities to nargenicin, which follow
the same trend (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>A). We also tested the resistant mutation in <italic>S. aureus</italic> DnaE (S765L), which, as predicted, reduced the affinity for DNA,
approximately 14-fold (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>D).</p><fig id="fig5" position="float"><label>Figure 5</label><caption><p>Sensitivity to nargenicin is dependent on the DNA binding affinity.
(A) Nargenicin binding site in a computational model of <italic>S. aureus</italic> DnaE. The modeled nargenicin is shown in
transparent sticks, and the three residues that make a hydrogen bond
to nargenicin in <italic>Mtb</italic> DnaE1 are labeled. The view
is identical to <xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>F. (B) Nargenicin binding site in the crystal structure of <italic>E. coli</italic> Pol III&#x003b1;. The modeled nargenicin is
shown in transparent sticks, and the three residues that make a hydrogen
bond to nargenicin in <italic>Mtb</italic> DnaE1 are labeled. The
view is identical to <xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>F. (C) Nargenicin resistance mutation in <italic>S.
aureus</italic> DnaE mapped onto <italic>Mtb</italic> DnaE1,
shown by a magenta sphere, is located 30 &#x000c5; away from the nargenicin
(shown in yellow sticks) but is adjacent to the dsDNA binding region
of the polymerase. Residues that interact with the DNA backbone are
shown in green sticks. (D) Fluorescence anisotropy DNA binding curves
of <italic>S. aureus</italic> DnaE (green line), <italic>Mtb</italic> DnaE1 (orange line), and <italic>E. coli</italic> Pol III&#x003b1; (blue line) show dissociation constants of 6 nM,
250 nM, and 12 &#x003bc;M, respectively. <italic>S. aureus</italic> DnaE<sup>S765L</sup> (green dashed line), which carries a mutation
that confers antibiotic resistance, shows a dissociation constant
of 85 nM, which is &#x0223c;14-fold increased, as compared to the wild
type.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="id1c00643_0006" id="gr5" position="float"/></fig><p>Taken together, these data support
the notion that the potential
of nargenicin to inhibit a DNA polymerase is dependent on the polymerase&#x02019;s
affinity for DNA, and any changes which reduce the DNA affinity, lead
to reduced nargenicin potency, either through natural variation, as
in the case of <italic>E. coli</italic> Pol III&#x003b1;,
or through a resistance-conferring mutation,<sup><xref ref-type="bibr" rid="ref18">18</xref></sup> as for <italic>S. aureus</italic> DnaE. Importantly, <italic>S. aureus</italic> engages two essential DNA polymerases at
the replication fork, namely, PolC and DnaE;<sup><xref ref-type="bibr" rid="ref46">46</xref></sup> if the activity of one is impaired, the other may compensate. However,
mycobacteria rely on only one replicative polymerase, DnaE1. Therefore,
nargenicin resistance-conferring mutations in DnaE1 could have catastrophic
consequences in mycobacteria, which might explain our inability to
isolate spontaneous resistant mutants in <italic>Mtb</italic> or <italic>Msm</italic>.</p></sec></sec><sec id="sec3"><title>Discussion</title><p>We have reported multiple
lines of evidence that nargenicin acts
as a DNA replication inhibitor in mycobacteria by targeting the essential
DnaE1 polymerase, an enzyme identified recently as a highly vulnerable
component of the DNA replication machinery in <italic>Mtb</italic>.<sup><xref ref-type="bibr" rid="ref9">9</xref></sup> Unlike the commonly used nucleotide
analogues that act as chain terminators through the incorporation
into the nascent DNA strand, nargenicin does not become incorporated
into the DNA. Instead, it is wedged between the terminal base pair
of the DNA substrate and the polymerase fingers domain, occupying
both the position of the incoming nucleotide and the templating base,
which is displaced by nargenicin. This binding mode is analogous to
that of the human Pol &#x003b1; inhibitor, aphidicolin, which is derived
from the fungus, <italic>Cephalosporium aphidicola</italic>, and unrelated in structure to nargenicin, indicating that these
inhibitors have evolved independently. This unusual mechanism might
explain the observation that the antimycobacterial activity of nargenicin
was not diminished by overexpression of the cognate target, DnaE1.
Based on this mechanism, the DnaE homologue in the <italic>Nocardia</italic> sp. CS682 producer organism would presumably need to bind nargenicin
in a DNA-independent manner to fulfill its postulated &#x0201c;decoy&#x0201d;
role in self-resistance.<sup><xref ref-type="bibr" rid="ref21">21</xref></sup></p><p>Nargenicin-mediated
disruption of replisome function triggers a
physiological response in <italic>Mtb</italic>, which resembles that
elicited by genotoxins, which cause double-stranded breaks (DSBs)
(mitomycin C, fluoroquinolones).<sup><xref ref-type="bibr" rid="ref35">35</xref></sup> This
features upregulation of genes encoding the recombinase involved in
recombination repair (<italic>recA</italic>), the mutasome responsible
for DNA-damage-induced mutagenesis and damage tolerance (<italic>dnaE2</italic>, <italic>imuA</italic>&#x02032;, <italic>imuB</italic>),<sup><xref ref-type="bibr" rid="ref35">35</xref>,<xref ref-type="bibr" rid="ref36">36</xref></sup> the PafBC-regulated DSB-resecting motor-nuclease (<italic>adnAB</italic>)<sup><xref ref-type="bibr" rid="ref37">37</xref>,<xref ref-type="bibr" rid="ref47">47</xref></sup> and a cell wall hydrolase (<italic>chiZ</italic>),<sup><xref ref-type="bibr" rid="ref48">48</xref></sup> among other DNA-damage-responsive
genes in mycobacteria. The DNA damage response to nargenicin begs
the question of whether pharmacological inhibition of DnaE1 by this
or other inhibitors might have the unintended consequence of inducing
chromosomal mutations, which could fuel the evolution of drug resistance,
as documented for sublethal treatment of mycobacteria and other organisms
by fluoroquinolones.<sup><xref ref-type="bibr" rid="ref49">49</xref>,<xref ref-type="bibr" rid="ref50">50</xref></sup> The concomitant downregulation
of <italic>ftsZ</italic>,<sup><xref ref-type="bibr" rid="ref39">39</xref></sup><italic>sepF</italic>,<sup><xref ref-type="bibr" rid="ref51">51</xref></sup><italic>whiB2</italic>,<sup><xref ref-type="bibr" rid="ref52">52</xref></sup> and <italic>ripA</italic>(<xref ref-type="bibr" rid="ref51">51</xref>) is consistent with cellular elongation, resulting from
a block in cell division, followed by cell death. Ablation of the
SOS response by deletion of <italic>recA</italic>, or a key component
thereof (mutasome function) by deletion of <italic>dnaE2</italic>,
had no discernible impact on the antimycobacterial activity of nargenicin,
suggesting that the LexA/RecA-dependent DNA repair, damage tolerance,
and (SOS) mutagenesis systems are unable to rescue mycobacteria from
the growth inhibitory effects of nargenicin. Instead, an arrest in
cell division, as evidenced by bacillary elongation, appears to precede
cell death. However, the DNA damage response to nargenicin also includes
genes such as <italic>adnA</italic>, <italic>adnB</italic>, <italic>cho</italic>, and <italic>uvrA</italic>, which form part of the mycobacterial
LexA/RecA-independent regulon controlled by PafBC.<sup><xref ref-type="bibr" rid="ref37">37</xref>,<xref ref-type="bibr" rid="ref53">53</xref></sup> Given that <italic>adnA</italic>, <italic>adnB</italic>, and <italic>lhr</italic> are among the genes most highly upregulated by nargenicin
treatment, it will be important to establish whether, under which
conditions, and to what extent the functional disruption of this regulon
might have on the susceptibility of mycobacteria to this compound.</p><p>Another feature of the nargenicin mode of action was the late,
strong signal elicited in the GFP release assay. The induction of <italic>chiZ</italic> and downregulation of <italic>fbpC</italic> might be
telling in this regard: first, the damage-inducible protein, ChiZ,<sup><xref ref-type="bibr" rid="ref54">54</xref></sup> has been reported to arrest cell division, increase
filamentation, and induce cell lysis when overexpressed.<sup><xref ref-type="bibr" rid="ref48">48</xref></sup> Second, inactivation of the mycolyltransferase,
FbpC, a member of the antigen 85 complex involved in the synthesis
of trehalose dimycolate and mycolylarabinogalactan, which are key
components of the mycobacterial cell envelope, has been shown to significantly
reduce the mycolate content and increase the permeability of the cell
envelope to small hydrophobic and hydrophilic molecules.<sup><xref ref-type="bibr" rid="ref55">55</xref></sup> Thus, in addition to its replication-arresting
activity, nargenicin may also compromise the integrity of the mycobacterial
outer membrane and thus act as a potentiator of other antitubercular
agents whose efficacy is limited by permeation across the mycobacterial
cell envelope.</p></sec><sec id="sec4"><title>Conclusions</title><p>In conclusion, we have
shown that nargenicin mediates its bactericidal
activity against <italic>M. tuberculosis</italic> through
interaction with DnaE1 in a manner that depends upon the presence
of the DNA substrate. In this interaction, the nargenicin molecule
wedges itself between DnaE1 and the terminal base pair of the DNA
and occupies the place of both the incoming nucleotide and the templating
base. By analyzing the physiological consequences of <italic>Mtb</italic> exposure to nargenicin, we show that the arrest in bacillary replication
resulting from the nargenicin-DnaE1 interaction triggers induction
of a DNA damage response coupled with an arrest in cell division and
an apparent weakening of the mycobacterial cell envelope. In addition
to strongly reaffirming the value of natural products as a source
of novel antitubercular agents, this work has provided the rationale
and platform for focusing target-led drug discovery efforts on a promising
new TB drug target.</p></sec><sec id="sec5"><title>Methods</title><sec id="sec5.1"><title>Bacterial Strains, Culture
Conditions, and Media</title><p>The
strains used in this study are listed in the <bold>key resources table</bold>. These include the parental wild-type strains, <italic>Mtb</italic> H37Rv<sup><xref ref-type="bibr" rid="ref56">56</xref></sup> and <italic>Msm</italic> mc<sup>2</sup>155.<sup><xref ref-type="bibr" rid="ref57">57</xref></sup> Clinical isolates were obtained
from samples collected from new TB cases and retreatment cases of
subjects who were enrolled in a prospective longitudinal cohort study
(ClinicalTrials.gov identifier, NCT00341601) at the National Masan
Tuberculosis Hospital in the Republic of Korea from May 2005 to December
2006.<sup><xref ref-type="bibr" rid="ref58">58</xref></sup> Mycobacterial strains were cultured
in various media depending on the assay. 7H9 OADC was prepared by
supplementing Middlebrook 7H9 (Difco) with 10% oleic acid-albumin-dextrose-catalase
(OADC) enrichment (Difco), 0.2% glycerol, and either 0.05% Tween-80
(7H9/OADC/Tw) or 0.05% Tyloxapol (7H9/OADC/Tx). 7H9/Glu/ADC/Tw medium
was prepared by substituting 10% OADC with 10% albumin-dextrose-catalase
(ADC) enrichment (Difco). Similarly, 7H9/Glu/CAS/Tx was prepared by
supplementing 7H9 with 0.4% glucose, 0.03% casitone (CAS), 0.081%
NaCl, and 0.05% Tx. Glycerol-alanine-salts with iron (GAST-Fe/Tw)
medium, pH 6.6, was prepared with 0.03% CAS, 0.005% ferric ammonium
citrate, 0.4% dibasic potassium phosphate, 0.2% citric acid, 0.1% <sc>l</sc>-alanine, 0.12% MgCl<sub>2</sub>, 0.06% potassium sulfate,
0.2% ammonium chloride, 0.018% of a 1% sodium hydroxide solution,
1% glycerol, and 0.05% Tween-80. GAST/Tw, an iron limiting media,
was prepared as described above but excluding ferric ammonium citrate.
All <italic>Mtb</italic> cultures were incubated at 37 &#x000b0;C in
sealed culture flasks with no agitation. The cells were plated onto
Middlebrook 7H10 agar plates with a 7H10 agar base (Difco) supplemented
with 10% OADC and 0.5% glycerol. Unless indicated otherwise, microbiological
assays using the strains described below were performed in 7H9/OADC/Tw
media.</p><p>The fluorescent reporter strain H37Rv-GFP<sup><xref ref-type="bibr" rid="ref59">59</xref></sup> and bioluminescent reporter strain P<italic>recA</italic>-LUX<sup><xref ref-type="bibr" rid="ref33">33</xref></sup> were grown in media
supplemented with kanamycin (Kan) at 20 &#x003bc;g/mL, whereas the <italic>Mtb</italic> mScarlet strain and <italic>Msm</italic> &#x00394;L mutant
were grown in media supplemented with hygromycin (Hyg) at 50 &#x003bc;g/mL. <italic>Mtb</italic> and <italic>Msm</italic> strains carrying the P<sub><italic>UV15-Tet</italic></sub>-<italic>dnaE1</italic>-<italic>MYC</italic>::L5 vector<sup><xref ref-type="bibr" rid="ref41">41</xref></sup> were grown in
media containing Kan at 50 &#x003bc;g/mL and supplemented with ATc at
100 ng/mL to induce expression of <italic>dnaE1</italic>. The inducible
CRISPRi hypomorphs were grown in media containing Kan (25 &#x003bc;g/mL)
and Hyg (50 &#x003bc;g/mL) and supplemented with ATc at 100 ng/mL to
induce transcriptional silencing. Minimal inhibitory concentrations
(MICs) were determined against a range of clinical isolates: <italic>Mtb</italic> CDC1551;<sup><xref ref-type="bibr" rid="ref60">60</xref></sup><italic>Mtb</italic> HN878;<sup><xref ref-type="bibr" rid="ref61">61</xref></sup> drug susceptible isolates, <italic>Mtb</italic> 0A029, <italic>Mtb</italic> 0A031 and <italic>Mtb</italic> 0B229; multi-drug resistant isolates, <italic>Mtb</italic> 0B123
resistant to isoniazid (INH<sup>R</sup>), ofloxacin (OFX<sup>R</sup>), <italic>para</italic>-amino salicylic acid (PAS<sup>R</sup>),
streptomycin (STR<sup>R</sup>), rifampicin (RIF<sup>R</sup>); <italic>Mtb</italic> 0A024 (ethambutol (EMB<sup>R</sup>), INH<sup>R</sup>, kanamycin (KAN<sup>R</sup>), PAS<sup>R</sup>, pyrazinamide (PZA<sup>R</sup>), STR<sup>R</sup>, ethionamide (ETH<sup>R</sup>), RIF<sup>R</sup>, <italic>Mtb</italic> 0B026 (EMB<sup>R</sup>, INH<sup>R</sup>, KAN<sup>R</sup>, PAS<sup>R</sup>, RIF<sup>R</sup>); and an extensively
drug resistant strain, <italic>Mtb</italic> 0B014 (EMB<sup>R</sup>, INH<sup>R</sup>, KAN<sup>R</sup>, OFX<sup>R</sup>, PAS<sup>R</sup>, RIF<sup>R</sup>).<sup><xref ref-type="bibr" rid="ref58">58</xref></sup></p></sec><sec id="sec5.2"><title>Drug Susceptibility
Testing</title><p>MIC testing was performed
by broth microdilution assay<sup><xref ref-type="bibr" rid="ref59">59</xref></sup> and quantitatively
analyzed with the colorimetric alamarBlue cell viability reagent (Thermo
Fischer Scientific), as previously described.<sup><xref ref-type="bibr" rid="ref32">32</xref></sup></p></sec><sec id="sec5.3"><title>Bioluminescence Assay</title><p>P<italic>recA</italic>-LUX<sup><xref ref-type="bibr" rid="ref33">33</xref></sup> was grown to an OD<sub>600</sub> of &#x0223c;0.4,
diluted 10-fold in 7H9/OADC/Tw, and inoculated into white, clear-bottom,
96-well microtiter plates (Greiner CellStar) containing two-fold serial
dilutions of the drug. The plates were incubated at 37 &#x000b0;C, and
luminescence was recorded every 24 h for 8 days using a SpectraMax
i3x plate reader (Molecular Devices). Data were plotted in Prism 9
(GraphPad).</p></sec><sec id="sec5.4"><title>GFP Release Assay</title><p>As described previously,<sup><xref ref-type="bibr" rid="ref32">32</xref></sup> H37Rv-GFP was grown to an OD<sub>600</sub> of
&#x0223c;0.3 in 7H9 OADC and exposed to the drug at 1&#x000d7; or 10&#x000d7;
MIC. Every 24 h, over a period of 8 days, 200 &#x003bc;L of culture
was harvested, pelleted by centrifugation, and the supernatant was
transferred to a black, clear-bottom 96-well microtiter plate (Greiner
CellStar) and the fluorescence (excitation, 540 nm; emission, 590
nm) was measured using a SpectraMax i3x plate reader (Molecular Devices).
Fluorescence intensity was normalized by OD<sub>650</sub> and standardized
to the value of the drug-free control for each sample.</p></sec><sec id="sec5.5"><title>Time&#x02013;Kill
Kinetics</title><p><italic>Mtb</italic> was
inoculated in the culture medium at an OD<sub>600</sub> of 0.002,
and the drug was added at a concentration of either 1&#x000d7;, 5&#x000d7;,
or 10&#x000d7; MIC. Cultures were incubated in sealed culture flasks,
and 1 mL aliquot was harvested every 24 h over 8 days. The samples
were washed twice in fresh media. One hundred &#x003bc;L aliquots of
10-fold serial dilutions were plated of 7H11 agar, and colony-forming
units (CFUs) were enumerated after incubation for 3&#x02013;4 weeks.</p></sec><sec id="sec5.6"><title>Macromolecular Incorporation Assays</title><p>Macromolecular
incorporation assays were performed as described.<sup><xref ref-type="bibr" rid="ref62">62</xref>,<xref ref-type="bibr" rid="ref63">63</xref></sup> Briefly, <italic>Mtb</italic> cultures were grown to early exponential
phase (OD<sub>600</sub> of &#x0223c;0.3) and 1 &#x003bc;Ci/mL [<sup>3</sup>H]-uracil, 2.5 &#x003bc;Ci/mL [3H]-phenylalanine, 10 &#x003bc;Ci/mL [<sup>3</sup>H]-N-acetyl glucosamine, and 1 &#x003bc;Ci/mL [<sup>14</sup>C]-acetate were added to quantify the incorporation of the radiolabeled
precursors into either total nucleic acid (i.e., DNA and RNA), protein,
cell wall, or fatty acids, respectively. The cells were incubated
at 37 &#x000b0;C for 1 h, and 150 &#x003bc;L was transferred to 96-well
microtiter plates containing 150 &#x003bc;L of each test compound. Nargenicin
was used at 2&#x000d7; and 20&#x000d7; MIC with 1% DMSO included as an untreated
control. The specificity of assays was monitored by the inclusion
of the pathway-specific antibiotics OFX (5 &#x003bc;g/mL), STR (10 &#x003bc;g/mL), <sc>d</sc>-cycloserine (DCS, 5 &#x003bc;g/mL), and INH (0.2 &#x003bc;g/mL)
as positive controls. The assay plates were incubated at 37 &#x000b0;C
for 24 h, and precursor incorporation was terminated by the addition
of 300 &#x003bc;L of 20% trichloroacetic acid (TCA). The samples were
incubated at 4 &#x000b0;C for 1 h, and the precipitates were collected
by vacuum filtration with a 96-well MultiScreen GFC glass fiber plate
(Millipore). Precipitates were washed three times with 10% TCA, followed
by three 95% ethanol washes, and the plates were allowed to air-dry.
Precipitates were resuspended in 50 &#x003bc;L of MicroScint 20 (PerkinElmer),
and the radioactivity on each filter was measured in a MicroBeta Liquid
Scintillation Counter (PerkinElmer). To distinguish between the incorporation
of [<sup>3</sup>H]-uracil into DNA vs. RNA, the RNA was hydrolyzed
with 500 &#x003bc;L of 1 M KOH at 37 &#x000b0;C for 16 h and neutralized
with 125 &#x003bc;L of HCl. The samples were then precipitated by adding
625 &#x003bc;L of 20% TCA, and the amount of residual radioactivity
present in the DNA precipitates was quantified following filtration
and washing as described above. All samples were analyzed in duplicate,
and the results represent the percentage of radiolabel incorporation
relative to the DMSO-treated control from two independent replicates.</p></sec><sec id="sec5.7"><title>Microscopy</title><p><italic>Msm</italic> bacilli were imaged
to determine their terminal phenotypes under exposure to varying concentrations
of antibiotics as previously described.<sup><xref ref-type="bibr" rid="ref39">39</xref></sup> Strains were grown to late-log phase (OD<sub>600</sub> of &#x0223c;0.8),
filtered once through a Millex syringe filter (5 &#x003bc;m pore size,
Millipore), and diluted (1:40) into fresh media. The samples were
left untreated, exposed to the carrier (DMSO only) or to the varying
concentrations of nargenicin in DMSO (1&#x000d7; MIC, 2&#x000d7; MIC, 4&#x000d7;
MIC), and incubated for 18 h at 37 &#x000b0;C while shaking. After exposure,
the cultures were spotted on low-melt agarose pads and imaged on a
ZEISS Axio Observer using a 100&#x000d7;, 1.4 NA objective with Phase
Contrast and Colibri 7 fluorescent illumination system. Images were
captured using a Zeiss Axiocam 503. Image processing, cell measurements,
and analysis were performed in the FIJI Plugin,<sup><xref ref-type="bibr" rid="ref64">64</xref></sup> MicrobeJ,<sup><xref ref-type="bibr" rid="ref65">65</xref></sup> R,<sup><xref ref-type="bibr" rid="ref66">66</xref></sup> and UMAP, as described.<sup><xref ref-type="bibr" rid="ref39">39</xref></sup></p></sec><sec id="sec5.8"><title>Transcriptional Profiling</title><p>Microarray experiments and
analyses were performed by the NIAID Microarray Research Facility,
as previously described,<sup><xref ref-type="bibr" rid="ref35">35</xref></sup> including two
independent samples for each treatment condition. Datasets from cultures
exposed to mitomycin C (0.2 &#x003bc;g/mL) and levofloxacin (10 &#x003bc;g/mL)
were compared to nargenicin (129 &#x003bc;g/mL). The top 300 upregulated
or downregulated genes, ranked by the average Log&#x0202f;2 fold-change
in expression data from two biological repeats, were compared to generate
gene shortlists common to all three treatments.</p><p>For RNA-seq,
qRT-PCR, and microarray experiments, <italic>Mtb</italic> cultures
(20&#x02013;30 mL) were grown either in roller bottles or culture flasks
on a shaker to mid-exponential phase (OD<sub>600</sub> of &#x0223c;0.3&#x02013;0.5)
prior to treatment with nargenicin at 1&#x000d7; or 10&#x000d7; MIC for
6 h. The cells were harvested by centrifugation at 3000<italic>g</italic> for 10 min and resuspended in 1 mL of Qiazol Lysis Reagent (Qiagen).
The cells were lysed with 0.1 mm Zirconia/Silica beads (BioSpec) in
a MagNA Lyser Homogenizer (Roche) (6000 rpm, 30 s) three times with
1 min cooling intervals. The samples were centrifuged at 10&#x0202f;000<italic>g</italic> for 5 min at 4 &#x000b0;C, and the supernatant was transferred
into a clean tube containing an equal volume of 100% ethanol. The
RNA was purified and treated with DNase on-column using the Direct-zol
RNA MiniPrep kit (Zymo Research) according to the manufacturer&#x02019;s
protocol. The samples were eluted in 50 &#x003bc;L of RNase- and DNase-free
water. Purified RNA was treated with DNase for an additional 60 min
at 37 &#x000b0;C using the TURBO DNA-free kit (Ambion) according to the
manufacturer&#x02019;s protocol. In preparation for microarray analysis
and RNA-seq, the sample quality was confirmed using a Bioanalyzer
RNA 6000 Nano Kit and Chips (Agilent). For RNA-seq experiments, three
independent biological replicates of both nargenicin-treated (10&#x000d7;
MIC) and untreated samples were performed. Library preparation and
sequencing were done by Admera Health (NJ) using the Illumina NovaSeq
S4 sequencing platform. The sequencing strategy included an average
of 60 million 150 bp paired-end reads per sample. Reads were demultiplexed
to generate raw fastq files for each sample and data were deposited
in the NCBI SRA repository (PRJNA722614). Initial quality control
(QC) of the raw fastQ files was performed using FastQC.<sup><xref ref-type="bibr" rid="ref67">67</xref></sup> Reads were trimmed and adapters were removed
using Trim Galore. Further QC was done by aligning reads using BWA
to the reference genome of <italic>Mtb</italic> H37Rv, ASM19595v2,
GenBank assembly accession no. GCA_000195955.2 (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/assembly/GCF_000195955.2">https://www.ncbi.nlm.nih.gov/assembly/GCF_000195955.2</uri>), running RSeQC<sup><xref ref-type="bibr" rid="ref68">68</xref></sup> and dupRadar,<sup><xref ref-type="bibr" rid="ref69">69</xref></sup> and an amalgamated report generated using MultiQC.<sup><xref ref-type="bibr" rid="ref70">70</xref></sup> Transcript quantification was performed using
Salmon in a mapping-based mode.<sup><xref ref-type="bibr" rid="ref71">71</xref></sup> Normalization
and differential expression analysis were done using DESeq. 2<sup><xref ref-type="bibr" rid="ref72">72</xref></sup> with count normalization by DESeq. 2&#x02019;s
median or ratios. <italic>P</italic>-values were adjusted for multiple
testing using the Benjamini&#x02013;Hochberg approach, and genes that
displayed an absolute Log&#x0202f;2 fold-change &#x0003e;1 and an adjusted <italic>p</italic>-value &#x0003c;0.05 were considered differentially expressed.
Data were visualized in <italic>R</italic>, and the functional enrichment
of upregulated and downregulated shortlists as compared to the full
genome was performed in STRING<sup><xref ref-type="bibr" rid="ref73">73</xref></sup> using
Gene Ontologies, STRING local network clusters, annotated keywords,
KEGG pathways, and InterPro protein domains and features as categories.
Multiple comparisons were compensated for using the false discovery
rate (FDR), with significant enrichment considered as FDR &#x0003e; 0.05.</p><p>For qRT-PCR experiments, following TURBO DNase treatment, 250 ng
of the RNA was converted to cDNA using SuperScript IV Reverse Transcriptase
(Thermo Fischer Scientific). Regions of interest were amplified using
primer pairs described in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.1c00643/suppl_file/id1c00643_si_001.pdf">Table S3</ext-link> and
Power SYBR Green PCR master mix (Thermo Fischer Scientific), and transcript
levels for three independent samples were quantified on a PikoReal
real-time PCR system (Thermo Fischer Scientific). Transcript levels
of target genes were normalized to <italic>sigA</italic>.</p></sec><sec id="sec5.9"><title>Construction
of Fluorescent dnaE1 Hypomorphs</title><p>The ATc-regulated
CRISPRi system developed by Rock et al.<sup><xref ref-type="bibr" rid="ref40">40</xref></sup> was used to construct inducible <italic>dnaE1</italic>-targeting <italic>Mtb</italic> hypomorphs carrying the mScarlet fluorescence reporter.<sup><xref ref-type="bibr" rid="ref74">74</xref></sup> Briefly, two oligonucleotides complementary
to the dnaE1-targeting sequence (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.1c00643/suppl_file/id1c00643_si_001.pdf">Table S3</ext-link>) were annealed and cloned in pLJR965, and the presence of the sgRNA
was confirmed by Sanger sequencing. The sequence-verified constructs
were electroporated into <italic>Mtb</italic> mScarlet, selecting
on media supplemented with Kan (25 &#x003bc;g/mL) and Hyg (50 &#x003bc;g/mL).</p></sec><sec id="sec5.10"><title>Drug Susceptibility Testing Using Hypomorphs</title><p>To assess
the impact of <italic>dnaE1</italic> silencing on drug susceptibility,
the hypomorphs and vector control strains were grown to an OD<sub>600</sub> of 1.0 and diluted to an OD<sub>600</sub> of 0.01 in media
either with ATc (200 ng/mL) or without the inducer. Fifty &#x003bc;L
of the diluted culture was inoculated into each well of a MIC plate
containing 50 &#x003bc;L of media with 2-fold dilutions of the drug.
Microtiter plates were incubated at 37 &#x000b0;C for 14 days, and the
fluorescence (594 nm, excitation; and 569 nm, emission) was recorded
using a Spectramax i3x plate reader. Each strain was normalized to
the no-drug control to determine the percentage growth inhibition
as a function of drug concentration. Dose&#x02013;response curves were
plotted in Prism 9 (GraphPad).</p></sec><sec id="sec5.11"><title>Protein Expression and
Purification</title><p><italic>Mtb</italic> DnaE1 was expressed in <italic>Msm</italic> and purified as previously
described.<sup><xref ref-type="bibr" rid="ref41">41</xref></sup><italic>S. aureus</italic> DnaE and <italic>E. coli</italic> Pol III&#x003b1; were
expressed in <italic>E. coli</italic> BL21 and purified
as previously described.<sup><xref ref-type="bibr" rid="ref18">18</xref>,<xref ref-type="bibr" rid="ref75">75</xref></sup></p></sec><sec id="sec5.12"><title>DNA Polymerase
Assay</title><p>DNA polymerase activity was measured
using a real-time polymerase assay as described previously.<sup><xref ref-type="bibr" rid="ref41">41</xref></sup> Briefly, reactions were performed using 5 nM
DNA polymerase, 10 nM fluorescently labeled DNA substrate (Primer:
5&#x02032;-TAGGACGAAGGACTCCCAACTTTAGGTGCG, Template: 6-FAM-5&#x02032;-CCCCCCCCCATGCATGCGCACCTAAAGTTGGGAGTCCTTCGTCCTA),
and 100 nM unlabeled DNA substrate (same sequence as above). Reactions
contained 100 &#x003bc;M each dNTP, 5 mM MgSO<sub>4</sub>, 50 mM HEPES
pH 7.5, 100 mM potassium glutamate, 2 mM DTT, 0.5 mg/mL BSA, and 10
nM&#x02013;10 &#x003bc;M nargenicin, diluted from a stock of 10 mM in
100% DMSO. Then, 10 &#x003bc;L reactions were measured for 20 min at
24 &#x000b0;C in a 384-well plate using a Clariostar plate reader (BMG
LABTECH) with excitation and emission filters at 485 and 520 nm, respectively.</p></sec><sec id="sec5.13"><title>Fluorescence Anisotropy</title><p>DNA binding was measured using
a 5 nM Cy3-labeled DNA substrate (Primer: Cy3-5&#x02032;-GGTAACGCCAGGGTTTTCCCAGTC3,
Template 5&#x02032;-CGCTCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAACCCTGGCGTTACC)
and 1 nM&#x02013;40 &#x003bc;M DNA polymerase. Reaction conditions contained
25 mM HEPES (pH 7.5), 50 mM potassium glutamate, 2 mM DTT, and 0.5
mg/mL BSA. Then, 10 &#x003bc;L reactions were measured at 24 &#x000b0;C
in a 384-well plate using a Clariostar plate reader with excitation
and emission filters at 540 and 590 nm, respectively.</p></sec><sec id="sec5.14"><title>Cryo-EM Sample
Preparation and Imaging</title><p>Purified <italic>Mtb</italic> DnaE1
was diluted to 4 &#x003bc;M in 20 mM PIPES (pH 7.0),
50 mM potassium glutamate, 5 mM MgCl<sub>2</sub>, 2 mM DTT, and 0.01%
Tween-20. The diluted protein was incubated for 5 min with 10 &#x003bc;M
nargenicin (diluted from a stock of 10 mM in 100% DMSO) and 20 &#x003bc;M
DNA substrate (Template: 5&#x02032;- GATAGAGCAGAAGGACGAAGGACTCCCAACTTTAGGTG,
Primer: 5&#x02032;-GCACCTAAAGTTGGGAGTCCTTCGTCCT*T, where the asterisk
marks the position of a phosphorothioate bond). Then, 3 &#x003bc;L of
sample were adsorbed onto glow-discharged copper R2/1 holey carbon
grids (Quantifoil). Grids were glow discharged for 45 s at 25 mA using
an EMITECH K950 apparatus. Grids were blotted for one second at &#x0223c;80%
humidity at 4 &#x000b0;C and flash-frozen in liquid ethane using a Leica
EM GP plunge freezer. The grids were loaded into a Titan Krios (FEI)
electron microscope operating at 300 kV with a Gatan K3 detector.
The slit width of the energy filter was set to 20 eV. Images were
recorded with EPU software (Thermo Fisher Scientific) in the counting
mode. Dose, magnification, and pixel size are detailed in <xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>.</p><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><title>Cryo-EM Data Collection, Refinement,
and Validation Statistics</title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead><tr><th style="border:none;" align="center">data collection
and processing</th><th style="border:none;" align="left">&#x000a0;</th><th style="border:none;" align="center">model comparison</th><th style="border:none;" align="left">&#x000a0;</th></tr></thead><tbody><tr><td style="border:none;" align="left">magnification</td><td style="border:none;" align="left">&#x000d7;105&#x0202f;000</td><td style="border:none;" align="left">nonhydrogen atoms</td><td style="border:none;" align="left">8990</td></tr><tr><td style="border:none;" align="left">voltage (kV)</td><td style="border:none;" align="left">300</td><td style="border:none;" align="left">protein residues</td><td style="border:none;" align="left">1070</td></tr><tr><td style="border:none;" align="left">electron exposure e<sup>-</sup>/&#x000c5;<sup>2</sup></td><td style="border:none;" align="left">54</td><td style="border:none;" align="left">B factors (&#x000c5;<sup>2</sup>)</td><td style="border:none;" align="left">&#x000a0;</td></tr><tr><td style="border:none;" align="left">defocus range (&#x003bc;m)</td><td style="border:none;" align="left">0.8&#x02013;2.0</td><td style="border:none;" align="left">protein</td><td style="border:none;" align="left">21&#x02013;306</td></tr><tr><td style="border:none;" align="left">pixel size (&#x000c5;)</td><td style="border:none;" align="left">0.859</td><td style="border:none;" align="left">r.m.s deviations</td><td style="border:none;" align="left">&#x000a0;</td></tr><tr><td style="border:none;" align="left">symmetry
imposed</td><td style="border:none;" align="left">C1</td><td style="border:none;" align="left">bond lengths (&#x000c5;<sup>2</sup>)</td><td style="border:none;" align="left">0.0126</td></tr><tr><td style="border:none;" align="left">initial particle
images
(no)</td><td style="border:none;" align="left">2000000</td><td style="border:none;" align="left">bond angles (&#x000b0;)</td><td style="border:none;" align="left">1.1569</td></tr><tr><td style="border:none;" align="left">final particle images (no)</td><td style="border:none;" align="left">196709</td><td style="border:none;" align="left">validation</td><td style="border:none;" align="left">&#x000a0;</td></tr><tr><td style="border:none;" align="left">map resolution (&#x000c5;)</td><td style="border:none;" align="left">2.8</td><td style="border:none;" align="left">MolProbity score</td><td style="border:none;" align="left">1.47</td></tr><tr><td style="border:none;" align="left">FSC threshold</td><td style="border:none;" align="left">0.143</td><td style="border:none;" align="left">clashscore</td><td style="border:none;" align="left">4.22</td></tr><tr><td style="border:none;" align="left">map resolution range (&#x000c5;)</td><td style="border:none;" align="left">2.8 to &#x0003e; 5.5</td><td style="border:none;" align="left">poor rotamers (%)</td><td style="border:none;" align="left">1.28</td></tr></tbody></table><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead><tr><th style="border:none;" align="center">refinement</th><th style="border:none;" align="left">&#x000a0;</th><th style="border:none;" align="center">Ramachandran
plot</th><th style="border:none;" align="left">&#x000a0;</th></tr></thead><tbody><tr><td style="border:none;" align="left">initial model used</td><td style="border:none;" align="left">5LEW</td><td style="border:none;" align="left">favored (%)</td><td style="border:none;" align="left">96.90</td></tr><tr><td style="border:none;" align="left">model resolution
(&#x000c5;)</td><td style="border:none;" align="left">2.9</td><td style="border:none;" align="left">allowed (%)</td><td style="border:none;" align="left">3.10</td></tr><tr><td style="border:none;" align="left">FSC threshold</td><td style="border:none;" align="left">0.143</td><td style="border:none;" align="left">disallowed (%)</td><td style="border:none;" align="left">0</td></tr><tr><td style="border:none;" align="left">map sharpening B-factor
(&#x000c5;<sup>2</sup>)</td><td style="border:none;" align="left">&#x02013;50</td><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left">&#x000a0;</td></tr></tbody></table></table-wrap></sec><sec id="sec5.15"><title>Cryo-EM Image Processing</title><p>All image
processing was performed
using RELION 3.1.<sup><xref ref-type="bibr" rid="ref76">76</xref></sup> The images were drift
corrected using RELION&#x02019;s own (CPU-based) implementation of
the UCSF motioncor2, and defocus was estimated using gCTF.<sup><xref ref-type="bibr" rid="ref77">77</xref></sup> LoG-based auto-picking was performed on all
micrographs, and picked particles were 2D classified. After three
rounds of 2D classification, classes with different orientations were
selected for initial model generation in RELION. The initial model
was used as a reference for 3D classification into different classes.
The selected classes from 3D classification were subjected to 3D auto
refinement followed by different rounds of CTF refinement plus a final
round of Bayesian polishing. Polished particles were used for the
3D auto-refine job, and the final map was postprocessed to correct
for the modulation transfer function of the detector and sharpened
by applying a negative B-factor manually set to &#x02212;50. A soft
mask was applied during postprocessing to generate FSC curves to produce
a map of an average resolution of 2.9 &#x000c5;. The RELION postprocessed
map was used to generate improved-resolution EM maps using the SuperEM
method,<sup><xref ref-type="bibr" rid="ref78">78</xref></sup> which aided in model building
and refinement. Model building was performed using Coot,<sup><xref ref-type="bibr" rid="ref79">79</xref></sup> REFMAC5,<sup><xref ref-type="bibr" rid="ref80">80</xref></sup> the CCPEM-suite,<sup><xref ref-type="bibr" rid="ref81">81</xref></sup> and Phenix.<sup><xref ref-type="bibr" rid="ref82">82</xref></sup> Details
on model refinement and validation are shown in <xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>. In brief, model building started by the
rigid-body fitting of the known DnaE1 crystal structure (PDB 5LEW)<sup><xref ref-type="bibr" rid="ref42">42</xref></sup> into the experimental density map using Coot. The DNA molecule
was generated, and the rigid body was fitted into the experimental
density map using Coot. Next, we carried out one round of refinement
in REFMAC5 using jelly-body restraints, and the model was further
manually adjusted in Coot. Final refinement and model validation were
performed using Phenix.</p></sec><sec id="sec5.16"><title>Quantification and Statistical Analysis</title><p>Statistical
details are given in the <xref rid="sec5" ref-type="other">Methods sections</xref> and
figure legends, and these include details of the experiments, numbers
of replicates (technical and/or experimental), statistical software
used, and thresholds of significance. Significance was generally determined
as p&#x0003c;0.05, and correction for multiple comparisons was performed,
as appropriate. Independent experiments were performed a minimum of
two times, and these data were utilized for the generation of summary
statistics (mean and standard deviation). Replicate data are included
within each figure, as indicated in figure legends, else data are
described as a representative experiment. In addition, DNA polymerase
assays and DNA binding experiments were performed in three or more
independent experiments. Data were not excluded from experimental
datasets prior to or during analyses other than during cryo-EM data
processing, where particles that did not possess high-resolution features
were removed following standard procedures for cryo-EM structure determination.</p></sec></sec></body><back><notes id="notes-1" notes-type="si"><title>Supporting Information Available</title><p>The
Supporting Information
is available free of charge at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/10.1021/acsinfecdis.1c00643?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsinfecdis.1c00643</ext-link>.<list id="silist" list-type="simple"><list-item><p>Comparison of the transcriptional
response of <italic>Mtb</italic> to nargenicin <italic>versus</italic> other genotoxins;
binding of aphidicolin in human Pol &#x003b1;; antimycobacterial activity
of nargenicin; primers and other oligonucleotides (figures and tables)
(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.1c00643/suppl_file/id1c00643_si_001.pdf">PDF</ext-link>)</p></list-item><list-item><p>Dataset
S1 comprises output gene lists of RNA-seq differential
gene expression analysis and STRING functional analysis of significantly
differentially expressed genes (Data S1); related to <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref> and C (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.1c00643/suppl_file/id1c00643_si_002.xlsx">XLSX</ext-link>)</p></list-item></list></p></notes><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="sifile1"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="id1c00643_si_001.pdf"><caption><p>id1c00643_si_001.pdf</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="sifile2"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="id1c00643_si_002.xlsx"><caption><p>id1c00643_si_002.xlsx</p></caption></media></supplementary-material></sec><notes notes-type="accession-codes" id="notes-2"><title>Accession Codes</title><p>NCBI Sequence
Read Archive (SRA) repository (PRJNA722614).</p></notes><notes notes-type="" id="notes-5"><title>Author Present Address</title><p><sup>#</sup> Department of Biochemistry and Microbiology, Rhodes
University,
Grahamstown 6139, South Africa</p></notes><notes notes-type="" id="notes-6"><title>Author Contributions</title><p><sup>&#x02207;</sup> M.D.C.
and M.K.M. contributed equally to this paper. M.D.C. and
M.K.M. performed the microbiological profiling and RNA-seq experiments
and analyses; G.L.A. and H.I.M.B. performed the DNA microarray and
macromolecular incorporation assays; R.T. performed the polymerase
assays; A.B. and M.H.L. performed the cryo-EM; J.A. provided bioinformatics
support; and S.L. and Y.-M.A. provided technical support. The experiments
were designed and the data were analyzed by M.D.C., M.K.M., G.L.A.,
B.M.C., D.B.O., D.F.W., C.E.B.III, H.I.M.B., M.H.L., and V.M. This
manuscript was written by M.D.C., M.K.M., M.H.L., and V.M., and all
authors read and edited it. M.H.L., D.B.O., C.E.B.III, and V.M. were
Team Leads.</p></notes><notes notes-type="COI-statement" id="NOTES-d7e2150-autogenerated"><p>The authors declare the
following competing financial interest(s): B.M.C, K.Y. and D.B.O.
are employees of Merck Sharp &#x00026; Dohme Corp., a subsidiary of Merck
&#x00026; Co., Inc., Kenilworth, NJ, USA. C.E.B.III and V.M. are members
of the Editorial Advisory Board of <italic>ACS Infectious Diseases</italic>.</p></notes><notes notes-type="" id="notes-3"><title>Notes</title><p>Plasmids and bacterial strains generated for
this study are available upon request.</p></notes><notes notes-type="" id="notes-4"><title>Notes</title><p>RNA-seq datasets from this study are deposited
in the NCBI Sequence Read Archive (SRA) repository (PRJNA722614) and
are publicly available as of the date of publication. Atomic models
and cryo-EM maps have been deposited to the Protein Data Bank and
the Electron Microscopy Database under accession codes PDB 7PU7 and EMD 13654. The
paper does not report the original code. The pipeline for RNA-seq
analysis can be found at the GitHub repository (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/jambler24/bacterial_transcriptomics">https://github.com/jambler24/bacterial_transcriptomics</uri>). Microscopy data are available from the lead contact upon request.
Any additional information required to reanalyze the data reported
in this paper is available from the lead contact upon request.</p></notes><ack><title>Acknowledgments</title><p>This work was supported by grants from
the Bill &#x00026; Melinda
Gates Foundation (OPP1158806 to C.E.B.III and V.M.; INV-004757 to
V.M. and INV-002474 to M.H.L.), the Broad Institute (Turning the Tide
Against Tuberculosis program), the South African Medical Research
Council, the National Research Foundation of South Africa, the Oppenheimer
Memorial Trust, and an International Research Scholar&#x02019;s grant
from the HHMI (#55007649) (to V.M.), an African Career Accelerator
Award from the Crick African Network (to M.K.M.), and, in part, by
the Intramural Research Program of NIAID (to H.I.M.B. and C.E.B.III).
We acknowledge the use of the ilifu cloud computing facility (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.ilifu.ac.za">www.ilifu.ac.za</uri>) and thank Timothy
de Wet for advice and assistance with morphotyping experimentation
and analysis, Dirk Schnappinger and Jeremy Rock for kindly providing
reagents, and Curtis Englehart for technical advice.</p></ack><glossary id="dl1"><def-list><title>Abbreviations Used</title><def-item><term>ATc</term><def><p>anhydrotetracycline</p></def></def-item><def-item><term>cryo-EM</term><def><p>cryo-electron microscopy</p></def></def-item><def-item><term>DSB</term><def><p>double-stranded
breaks</p></def></def-item><def-item><term>GFP</term><def><p>green
fluorescent protein</p></def></def-item><def-item><term>MDR</term><def><p>multidrug resistant</p></def></def-item><def-item><term>MIC</term><def><p>minimum inhibitory concentration</p></def></def-item><def-item><term><italic>Msm</italic></term><def><p><italic>Mycobacterium
smegmatis</italic></p></def></def-item><def-item><term><italic>Mtb</italic></term><def><p><italic>Mycobacterium tuberculosis</italic></p></def></def-item><def-item><term>OB</term><def><p>oligonucleotide/oligosaccharide
binding</p></def></def-item><def-item><term>Pol III&#x003b1;</term><def><p>DNA polymerase III &#x003b1;</p></def></def-item><def-item><term>TB</term><def><p>tuberculosis</p></def></def-item><def-item><term>TBDA</term><def><p>Tuberculosis Drug Accelerator</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="report" id="cit1"><person-group person-group-type="allauthors"><collab>WHO</collab></person-group>. <source>Global Tuberculosis Report 2021</source>; <publisher-name>World Health Organisation</publisher-name>, <year>2021</year>.</mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="journal" id="cit2"><name><surname>Conradie</surname><given-names>F.</given-names></name>; <name><surname>Diacon</surname><given-names>A. H.</given-names></name>; <name><surname>Ngubane</surname><given-names>N.</given-names></name>; <name><surname>Howell</surname><given-names>P.</given-names></name>; <name><surname>Everitt</surname><given-names>D.</given-names></name>; <name><surname>Crook</surname><given-names>A. M.</given-names></name>; <name><surname>Mendel</surname><given-names>C. M.</given-names></name>; <name><surname>Egizi</surname><given-names>E.</given-names></name>; <name><surname>Moreira</surname><given-names>J.</given-names></name>; <name><surname>Timm</surname><given-names>J.</given-names></name>; <name><surname>McHugh</surname><given-names>T. D.</given-names></name>; <name><surname>Wills</surname><given-names>G. H.</given-names></name>; <name><surname>Bateson</surname><given-names>A.</given-names></name>; <name><surname>Hunt</surname><given-names>R.</given-names></name>; <name><surname>Van Niekerk</surname><given-names>C.</given-names></name>; <name><surname>Li</surname><given-names>M.</given-names></name>; <name><surname>Olugbosi</surname><given-names>M.</given-names></name>; <name><surname>Spigelman</surname><given-names>M.</given-names></name>
<article-title>Treatment of highly drug-resistant
pulmonary tuberculosis</article-title>. <source>N. Engl. J. Med.</source>
<year>2020</year>, <volume>382</volume>, <fpage>893</fpage>&#x02013;<lpage>902</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1901814</pub-id>.<pub-id pub-id-type="pmid">32130813</pub-id></mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="journal" id="cit3"><name><surname>Dorman</surname><given-names>S. E.</given-names></name>; <name><surname>Nahid</surname><given-names>P.</given-names></name>; <name><surname>Kurbatova</surname><given-names>E. V.</given-names></name>; <name><surname>Phillips</surname><given-names>P. P. J.</given-names></name>; <name><surname>Bryant</surname><given-names>K.</given-names></name>; <name><surname>Dooley</surname><given-names>K. E.</given-names></name>; <name><surname>Engle</surname><given-names>M.</given-names></name>; <name><surname>Goldberg</surname><given-names>S. V.</given-names></name>; <name><surname>Phan</surname><given-names>H. T. T.</given-names></name>; <name><surname>Hakim</surname><given-names>J.</given-names></name>; <name><surname>Johnson</surname><given-names>J. L.</given-names></name>; <name><surname>Lourens</surname><given-names>M.</given-names></name>; <name><surname>Martinson</surname><given-names>N. A.</given-names></name>; <name><surname>Muzanyi</surname><given-names>G.</given-names></name>; <name><surname>Narunsky</surname><given-names>K.</given-names></name>; <name><surname>Nerette</surname><given-names>S.</given-names></name>; <name><surname>Nguyen</surname><given-names>N. V.</given-names></name>; <name><surname>Pham</surname><given-names>T. H.</given-names></name>; <name><surname>Pierre</surname><given-names>S.</given-names></name>; <name><surname>Purfield</surname><given-names>A. E.</given-names></name>; <name><surname>Samaneka</surname><given-names>W.</given-names></name>; <name><surname>Savic</surname><given-names>R. M.</given-names></name>; <name><surname>Sanne</surname><given-names>I.</given-names></name>; <name><surname>Scott</surname><given-names>N. A.</given-names></name>; <name><surname>Shenje</surname><given-names>J.</given-names></name>; <name><surname>Sizemore</surname><given-names>E.</given-names></name>; <name><surname>Vernon</surname><given-names>A.</given-names></name>; <name><surname>Waja</surname><given-names>Z.</given-names></name>; <name><surname>Weiner</surname><given-names>M.</given-names></name>; <name><surname>Swindells</surname><given-names>S.</given-names></name>; <name><surname>Chaisson</surname><given-names>R. E.</given-names></name>
<article-title>Four-month rifapentine regimens with
or without moxifloxacin for tuberculosis</article-title>. <source>N.
Engl. J. Med.</source>
<year>2021</year>, <volume>384</volume>, <fpage>1705</fpage>&#x02013;<lpage>1718</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa2033400</pub-id>.<pub-id pub-id-type="pmid">33951360</pub-id></mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal" id="cit4"><name><surname>Evans</surname><given-names>J. C.</given-names></name>; <name><surname>Mizrahi</surname><given-names>V.</given-names></name>
<article-title>Priming the tuberculosis
drug pipeline: new antimycobacterial
targets and agents</article-title>. <source>Curr. Opin. Microbiol.</source>
<year>2018</year>, <volume>45</volume>, <fpage>39</fpage>&#x02013;<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1016/j.mib.2018.02.006</pub-id>.<pub-id pub-id-type="pmid">29482115</pub-id></mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal" id="cit5"><name><surname>Aldridge</surname><given-names>B. B.</given-names></name>; <name><surname>Barros-Aguirre</surname><given-names>D.</given-names></name>; <name><surname>Barry</surname><given-names>C. E.</given-names></name>; <name><surname>Bates</surname><given-names>R. H.</given-names></name>; <name><surname>Berthel</surname><given-names>S. J.</given-names></name>; <name><surname>Boshoff</surname><given-names>H. I.</given-names></name>; <name><surname>Chibale</surname><given-names>K.</given-names></name>; <name><surname>Chu</surname><given-names>X.-J.</given-names></name>; <name><surname>Cooper</surname><given-names>C. B.</given-names></name>; <name><surname>Dartois</surname><given-names>V.</given-names></name>; <name><surname>Duncan</surname><given-names>K.</given-names></name>; <name><surname>Fotouhi</surname><given-names>N.</given-names></name>; <name><surname>Gusovsky</surname><given-names>F.</given-names></name>; <name><surname>Hipskind</surname><given-names>P. A.</given-names></name>; <name><surname>Kempf</surname><given-names>D. J.</given-names></name>; <name><surname>Leli&#x000e8;vre</surname><given-names>J.</given-names></name>; <name><surname>Lenaerts</surname><given-names>A. J.</given-names></name>; <name><surname>McNamara</surname><given-names>C. W.</given-names></name>; <name><surname>Mizrahi</surname><given-names>V.</given-names></name>; <name><surname>Nathan</surname><given-names>C.</given-names></name>; <name><surname>Olsen</surname><given-names>D. B.</given-names></name>; <name><surname>Parish</surname><given-names>T.</given-names></name>; <name><surname>Petrassi</surname><given-names>H. M.</given-names></name>; <name><surname>Pym</surname><given-names>A.</given-names></name>; <name><surname>Rhee</surname><given-names>K. Y.</given-names></name>; <name><surname>Robertson</surname><given-names>G. T.</given-names></name>; <name><surname>Rock</surname><given-names>J. M.</given-names></name>; <name><surname>Rubin</surname><given-names>E. J.</given-names></name>; <name><surname>Russell</surname><given-names>B.</given-names></name>; <name><surname>Russell</surname><given-names>D. G.</given-names></name>; <name><surname>Sacchettini</surname><given-names>J. C.</given-names></name>; <name><surname>Schnappinger</surname><given-names>D.</given-names></name>; <name><surname>Schrimpf</surname><given-names>M.</given-names></name>; <name><surname>Upton</surname><given-names>A. M.</given-names></name>; <name><surname>Warner</surname><given-names>P.</given-names></name>; <name><surname>Wyatt</surname><given-names>P. G.</given-names></name>; <name><surname>Yuan</surname><given-names>Y.</given-names></name>
<article-title>The Tuberculosis Drug
Accelerator
at year 10: what have we learned?</article-title>. <source>Nat. Med.</source>
<year>2021</year>, <volume>27</volume>, <fpage>1333</fpage>&#x02013;<lpage>1337</lpage>. <pub-id pub-id-type="doi">10.1038/s41591-021-01442-2</pub-id>.<pub-id pub-id-type="pmid">34226736</pub-id></mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal" id="cit6"><name><surname>Reiche</surname><given-names>M. A.</given-names></name>; <name><surname>Warner</surname><given-names>D. F.</given-names></name>; <name><surname>Mizrahi</surname><given-names>V.</given-names></name>
<article-title>Targeting
DNA replication and repair
for the development of novel therapeutics against tuberculosis</article-title>. <source>Front. Mol. Biosci.</source>
<year>2017</year>, <volume>4</volume>, <fpage>75</fpage><pub-id pub-id-type="doi">10.3389/fmolb.2017.00075</pub-id>.<pub-id pub-id-type="pmid">29184888</pub-id></mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal" id="cit7"><name><surname>Ditse</surname><given-names>Z.</given-names></name>; <name><surname>Lamers</surname><given-names>M. H.</given-names></name>; <name><surname>Warner</surname><given-names>D. F.</given-names></name>
<article-title>DNA replication
in <italic>Mycobacterium tuberculosis</italic></article-title>. <source>Microbiol. Spectrum</source>
<year>2017</year>, <volume>5</volume> (<issue>2</issue>), <fpage>1</fpage>&#x02013;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1128/microbiolspec.TBTB2-0027-2016</pub-id>.</mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal" id="cit8"><name><surname>de
Wet</surname><given-names>T. J.</given-names></name>; <name><surname>Warner</surname><given-names>D. F.</given-names></name>; <name><surname>Mizrahi</surname><given-names>V.</given-names></name>
<article-title>Harnessing biological
insight to accelerate tuberculosis drug discovery</article-title>. <source>Acc. Chem. Res.</source>
<year>2019</year>, <volume>52</volume>, <fpage>2340</fpage>&#x02013;<lpage>2348</lpage>. <pub-id pub-id-type="doi">10.1021/acs.accounts.9b00275</pub-id>.<pub-id pub-id-type="pmid">31361123</pub-id></mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal" id="cit9"><name><surname>Bosch</surname><given-names>B.</given-names></name>; <name><surname>DeJesus</surname><given-names>M. A.</given-names></name>; <name><surname>Poulton</surname><given-names>N. C.</given-names></name>; <name><surname>Zhang</surname><given-names>W.</given-names></name>; <name><surname>Engelhart</surname><given-names>C. A.</given-names></name>; <name><surname>Zaveri</surname><given-names>A.</given-names></name>; <name><surname>Lavalette</surname><given-names>S.</given-names></name>; <name><surname>Ruecker</surname><given-names>N.</given-names></name>; <name><surname>Trujillo</surname><given-names>C.</given-names></name>; <name><surname>Wallach</surname><given-names>J. B.</given-names></name>; <name><surname>Li</surname><given-names>S.</given-names></name>; <name><surname>Ehrt</surname><given-names>S.</given-names></name>; <name><surname>Chait</surname><given-names>B. T.</given-names></name>; <name><surname>Schnappinger</surname><given-names>D.</given-names></name>; <name><surname>Rock</surname><given-names>J. M.</given-names></name>
<article-title>Genome-wide gene expression tuning
reveals diverse vulnerabilities of <italic>M. tuberculosis</italic></article-title>. <source>Cell</source>
<year>2021</year>, <volume>184</volume>, <fpage>4579</fpage>&#x02013;<lpage>4592 e4524</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2021.06.033</pub-id>.<pub-id pub-id-type="pmid">34297925</pub-id></mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="book" id="cit10"><person-group person-group-type="allauthors"><name><surname>Mayer</surname><given-names>C.</given-names></name>; <name><surname>Takiff</surname><given-names>H.</given-names></name></person-group><article-title>The molecular
genetics of fluoroquinolone resistance in <italic>Mycobacterium
tuberculosis</italic></article-title>. In <source>Molecular
Genetics of Mycobacteria</source>; <publisher-name>John Wiley &#x00026;
Sons, Inc.</publisher-name>, <year>2014</year>; pp <fpage>455</fpage>&#x02013;<lpage>478</lpage>.</mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal" id="cit11"><name><surname>Nagaraja</surname><given-names>V.</given-names></name>; <name><surname>Godbole</surname><given-names>A. A.</given-names></name>; <name><surname>Henderson</surname><given-names>S. R.</given-names></name>; <name><surname>Maxwell</surname><given-names>A.</given-names></name>
<article-title>DNA topoisomerase I
and DNA gyrase as targets for TB therapy</article-title>. <source>Drug
Discovery Today</source>
<year>2017</year>, <volume>22</volume>, <fpage>510</fpage>&#x02013;<lpage>518</lpage>. <pub-id pub-id-type="doi">10.1016/j.drudis.2016.11.006</pub-id>.<pub-id pub-id-type="pmid">27856347</pub-id></mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal" id="cit12"><name><surname>Dawson</surname><given-names>R.</given-names></name>; <name><surname>Diacon</surname><given-names>A. H.</given-names></name>; <name><surname>Everitt</surname><given-names>D.</given-names></name>; <name><surname>van Niekerk</surname><given-names>C.</given-names></name>; <name><surname>Donald</surname><given-names>P. R.</given-names></name>; <name><surname>Burger</surname><given-names>D. A.</given-names></name>; <name><surname>Schall</surname><given-names>R.</given-names></name>; <name><surname>Spigelman</surname><given-names>M.</given-names></name>; <name><surname>Conradie</surname><given-names>A.</given-names></name>; <name><surname>Eisenach</surname><given-names>K.</given-names></name>; <name><surname>Venter</surname><given-names>A.</given-names></name>; <name><surname>Ive</surname><given-names>P.</given-names></name>; <name><surname>Page-Shipp</surname><given-names>L.</given-names></name>; <name><surname>Variava</surname><given-names>E.</given-names></name>; <name><surname>Reither</surname><given-names>K.</given-names></name>; <name><surname>Ntinginya</surname><given-names>N. E.</given-names></name>; <name><surname>Pym</surname><given-names>A.</given-names></name>; <name><surname>von Groote-Bidlingmaier</surname><given-names>F.</given-names></name>; <name><surname>Mendel</surname><given-names>C. M.</given-names></name>
<article-title>Efficiency and safety
of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide
during the first 8 weeks of antituberculosis treatment: a phase 2b,
open-label, partly randomised trial in patients with drug-susceptible
or drug-resistant pulmonary tuberculosis</article-title>. <source>Lancet</source>
<year>2015</year>, <volume>385</volume>, <fpage>1738</fpage>&#x02013;<lpage>1747</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(14)62002-X</pub-id>.<pub-id pub-id-type="pmid">25795076</pub-id></mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal" id="cit13"><name><surname>Das</surname><given-names>S.</given-names></name>; <name><surname>Garg</surname><given-names>T.</given-names></name>; <name><surname>Srinivas</surname><given-names>N.</given-names></name>; <name><surname>Dasgupta</surname><given-names>A.</given-names></name>; <name><surname>Chopra</surname><given-names>S.</given-names></name>
<article-title>Targeting
DNA gyrase to combat <italic>Mycobacterium tuberculosis</italic>: An update</article-title>. <source>Curr. Top. Med. Chem.</source>
<year>2019</year>, <volume>19</volume>, <fpage>579</fpage>&#x02013;<lpage>593</lpage>. <pub-id pub-id-type="doi">10.2174/1568026619666190304130218</pub-id>.<pub-id pub-id-type="pmid">30834837</pub-id></mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal" id="cit14"><name><surname>Johnson</surname><given-names>E. O.</given-names></name>; <name><surname>LaVerriere</surname><given-names>E.</given-names></name>; <name><surname>Office</surname><given-names>E.</given-names></name>; <name><surname>Stanley</surname><given-names>M.</given-names></name>; <name><surname>Meyer</surname><given-names>E.</given-names></name>; <name><surname>Kawate</surname><given-names>T.</given-names></name>; <name><surname>Gomez</surname><given-names>J. E.</given-names></name>; <name><surname>Audette</surname><given-names>R. E.</given-names></name>; <name><surname>Bandyopadhyay</surname><given-names>N.</given-names></name>; <name><surname>Betancourt</surname><given-names>N.</given-names></name>; <name><surname>Delano</surname><given-names>K.</given-names></name>; <name><surname>Da Silva</surname><given-names>I.</given-names></name>; <name><surname>Davis</surname><given-names>J.</given-names></name>; <name><surname>Gallo</surname><given-names>C.</given-names></name>; <name><surname>Gardner</surname><given-names>M.</given-names></name>; <name><surname>Golas</surname><given-names>A. J.</given-names></name>; <name><surname>Guinn</surname><given-names>K. M.</given-names></name>; <name><surname>Kennedy</surname><given-names>S.</given-names></name>; <name><surname>Korn</surname><given-names>R.</given-names></name>; <name><surname>McConnell</surname><given-names>J. A.</given-names></name>; <name><surname>Moss</surname><given-names>C. E.</given-names></name>; <name><surname>Murphy</surname><given-names>K. C.</given-names></name>; <name><surname>Nietupski</surname><given-names>R. M.</given-names></name>; <name><surname>Papavinasasundaram</surname><given-names>K. G.</given-names></name>; <name><surname>Pinkham</surname><given-names>J. T.</given-names></name>; <name><surname>Pino</surname><given-names>P. A.</given-names></name>; <name><surname>Proulx</surname><given-names>M. K.</given-names></name>; <name><surname>Ruecker</surname><given-names>N.</given-names></name>; <name><surname>Song</surname><given-names>N.</given-names></name>; <name><surname>Thompson</surname><given-names>M.</given-names></name>; <name><surname>Trujillo</surname><given-names>C.</given-names></name>; <name><surname>Wakabayashi</surname><given-names>S.</given-names></name>; <name><surname>Wallach</surname><given-names>J. B.</given-names></name>; <name><surname>Watson</surname><given-names>C.</given-names></name>; <name><surname>Ioerger</surname><given-names>T. R.</given-names></name>; <name><surname>Lander</surname><given-names>E. S.</given-names></name>; <name><surname>Hubbard</surname><given-names>B. K.</given-names></name>; <name><surname>Serrano-Wu</surname><given-names>M. H.</given-names></name>; <name><surname>Ehrt</surname><given-names>S.</given-names></name>; <name><surname>Fitzgerald</surname><given-names>M.</given-names></name>; <name><surname>Rubin</surname><given-names>E. J.</given-names></name>; <name><surname>Sassetti</surname><given-names>C. M.</given-names></name>; <name><surname>Schnappinger</surname><given-names>D.</given-names></name>; <name><surname>Hung</surname><given-names>D. T.</given-names></name>
<article-title>Large-scale chemical-genetics yields
new <italic>M. tuberculosis</italic> inhibitor classes</article-title>. <source>Nature</source>
<year>2019</year>, <volume>571</volume>, <fpage>72</fpage>&#x02013;<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-019-1315-z</pub-id>.<pub-id pub-id-type="pmid">31217586</pub-id></mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal" id="cit15"><name><surname>Godbole</surname><given-names>A. A.</given-names></name>; <name><surname>Ahmed</surname><given-names>W.</given-names></name>; <name><surname>Bhat</surname><given-names>R. S.</given-names></name>; <name><surname>Bradley</surname><given-names>E. K.</given-names></name>; <name><surname>Ekins</surname><given-names>S.</given-names></name>; <name><surname>Nagaraja</surname><given-names>V.</given-names></name>
<article-title>Targeting <italic>Mycobacterium tuberculosis</italic> topoisomerase I by small-molecule
inhibitors</article-title>. <source>Antimicrob. Agents Chemother.</source>
<year>2015</year>, <volume>59</volume>, <fpage>1549</fpage>&#x02013;<lpage>1557</lpage>. <pub-id pub-id-type="doi">10.1128/aac.04516-14</pub-id>.<pub-id pub-id-type="pmid">25534741</pub-id></mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal" id="cit16"><name><surname>Kaguni</surname><given-names>J. M.</given-names></name>
<article-title>The macromolecular
machines that duplicate the <italic>Escherichia coli</italic> chromosome as targets for drug discovery</article-title>. <source>Antibiotics</source>
<year>2018</year>, <volume>7</volume>, <fpage>23</fpage><pub-id pub-id-type="doi">10.3390/antibiotics7010023</pub-id>.</mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal" id="cit17"><name><surname>Kling</surname><given-names>A.</given-names></name>; <name><surname>Lukat</surname><given-names>P.</given-names></name>; <name><surname>Almeida</surname><given-names>D. V.</given-names></name>; <name><surname>Bauer</surname><given-names>A.</given-names></name>; <name><surname>Fontaine</surname><given-names>E.</given-names></name>; <name><surname>Sordello</surname><given-names>S.</given-names></name>; <name><surname>Zaburannyi</surname><given-names>N.</given-names></name>; <name><surname>Herrmann</surname><given-names>J.</given-names></name>; <name><surname>Wenzel</surname><given-names>S. C.</given-names></name>; <name><surname>K&#x000f6;nig</surname><given-names>C.</given-names></name>; <name><surname>Ammerman</surname><given-names>N. C.</given-names></name>; <name><surname>Barrio</surname><given-names>M. B.</given-names></name>; <name><surname>Borchers</surname><given-names>K.</given-names></name>; <name><surname>Bordon-Pallier</surname><given-names>F.</given-names></name>; <name><surname>Br&#x000f6;nstrup</surname><given-names>M.</given-names></name>; <name><surname>Courtemanche</surname><given-names>G.</given-names></name>; <name><surname>Gerlitz</surname><given-names>M.</given-names></name>; <name><surname>Geslin</surname><given-names>M.</given-names></name>; <name><surname>Hammann</surname><given-names>P.</given-names></name>; <name><surname>Heinz</surname><given-names>D. W.</given-names></name>; <name><surname>Hoffmann</surname><given-names>H.</given-names></name>; <name><surname>Klieber</surname><given-names>S.</given-names></name>; <name><surname>Kohlmann</surname><given-names>M.</given-names></name>; <name><surname>Kurz</surname><given-names>M.</given-names></name>; <name><surname>Lair</surname><given-names>C.</given-names></name>; <name><surname>Matter</surname><given-names>H.</given-names></name>; <name><surname>Nuermberger</surname><given-names>E.</given-names></name>; <name><surname>Tyagi</surname><given-names>S.</given-names></name>; <name><surname>Fraisse</surname><given-names>L.</given-names></name>; <name><surname>Grosset</surname><given-names>J. H.</given-names></name>; <name><surname>Lagrange</surname><given-names>S.</given-names></name>; <name><surname>M&#x000fc;ller</surname><given-names>R.</given-names></name>
<article-title>Targeting DnaN for tuberculosis therapy
using novel
griselimycins</article-title>. <source>Science</source>
<year>2015</year>, <volume>348</volume>, <fpage>1106</fpage>&#x02013;<lpage>1112</lpage>. <pub-id pub-id-type="doi">10.1126/science.aaa4690</pub-id>.<pub-id pub-id-type="pmid">26045430</pub-id></mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal" id="cit18"><name><surname>Painter</surname><given-names>R. E.</given-names></name>; <name><surname>Adam</surname><given-names>G. C.</given-names></name>; <name><surname>Arocho</surname><given-names>M.</given-names></name>; <name><surname>DiNunzio</surname><given-names>E.</given-names></name>; <name><surname>Donald</surname><given-names>R. G. K.</given-names></name>; <name><surname>Dorso</surname><given-names>K.</given-names></name>; <name><surname>Genilloud</surname><given-names>O.</given-names></name>; <name><surname>Gill</surname><given-names>C.</given-names></name>; <name><surname>Goetz</surname><given-names>M.</given-names></name>; <name><surname>Hairston</surname><given-names>N. N.</given-names></name>; <name><surname>Murgolo</surname><given-names>N.</given-names></name>; <name><surname>Nare</surname><given-names>B.</given-names></name>; <name><surname>Olsen</surname><given-names>D. B.</given-names></name>; <name><surname>Powles</surname><given-names>M.</given-names></name>; <name><surname>Racine</surname><given-names>F.</given-names></name>; <name><surname>Su</surname><given-names>J.</given-names></name>; <name><surname>Vicente</surname><given-names>F.</given-names></name>; <name><surname>Wisniewski</surname><given-names>D.</given-names></name>; <name><surname>Xiao</surname><given-names>L.</given-names></name>; <name><surname>Hammond</surname><given-names>M.</given-names></name>; <name><surname>Young</surname><given-names>K.</given-names></name>
<article-title>Elucidation
of dnaE as the antibacterial target of the natural product, nargenicin</article-title>. <source>Chem. Biol.</source>
<year>2015</year>, <volume>22</volume>, <fpage>1362</fpage>&#x02013;<lpage>1373</lpage>. <pub-id pub-id-type="doi">10.1016/j.chembiol.2015.08.015</pub-id>.<pub-id pub-id-type="pmid">26456734</pub-id></mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal" id="cit19"><name><surname>Cane</surname><given-names>D. E.</given-names></name>; <name><surname>Yang</surname><given-names>C. C.</given-names></name>
<article-title>Nargenicin biosynthesis:
late stage oxidations and
absolute configuration</article-title>. <source>J. Antibiot.</source>
<year>1985</year>, <volume>38</volume>, <fpage>423</fpage>&#x02013;<lpage>426</lpage>. <pub-id pub-id-type="doi">10.7164/antibiotics.38.423</pub-id>.</mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal" id="cit20"><name><surname>Celmer</surname><given-names>W. D.</given-names></name>; <name><surname>Chmurny</surname><given-names>G. N.</given-names></name>; <name><surname>Moppett</surname><given-names>C. E.</given-names></name>; <name><surname>Ware</surname><given-names>R. S.</given-names></name>; <name><surname>Watts</surname><given-names>P. C.</given-names></name>; <name><surname>Whipple</surname><given-names>E. B.</given-names></name>
<article-title>Structure of natural
antibiotic CP-47,444</article-title>. <source>J. Am. Chem. Soc.</source>
<year>1980</year>, <volume>102</volume>, <fpage>4203</fpage>&#x02013;<lpage>4209</lpage>. <pub-id pub-id-type="doi">10.1021/ja00532a036</pub-id>.</mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="journal" id="cit21"><name><surname>Pidot</surname><given-names>S. J.</given-names></name>; <name><surname>Rizzacasa</surname><given-names>M. A.</given-names></name>
<article-title>The nargenicin family of oxa-bridged
macrolide antibiotics</article-title>. <source>Chem. &#x02013; Eur. J.</source>
<year>2020</year>, <volume>26</volume>, <fpage>2780</fpage>&#x02013;<lpage>2792</lpage>. <pub-id pub-id-type="doi">10.1002/chem.201904053</pub-id>.<pub-id pub-id-type="pmid">31667915</pub-id></mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal" id="cit22"><name><surname>Sohng</surname><given-names>J. K.</given-names></name>; <name><surname>Yamaguchi</surname><given-names>T.</given-names></name>; <name><surname>Seong</surname><given-names>C. N.</given-names></name>; <name><surname>Baik</surname><given-names>K. S.</given-names></name>; <name><surname>Park</surname><given-names>S. C.</given-names></name>; <name><surname>Lee</surname><given-names>H. J.</given-names></name>; <name><surname>Jang</surname><given-names>S. Y.</given-names></name>; <name><surname>Simkhada</surname><given-names>J. R.</given-names></name>; <name><surname>Yoo</surname><given-names>J. C.</given-names></name>
<article-title>Production,
isolation and biological activity of nargenicin from Nocardia sp.
CS682</article-title>. <source>Arch. Pharmacal Res.</source>
<year>2008</year>, <volume>31</volume>, <fpage>1339</fpage>&#x02013;<lpage>1345</lpage>. <pub-id pub-id-type="doi">10.1007/s12272-001-2115-0</pub-id>.</mixed-citation></ref><ref id="ref23"><mixed-citation publication-type="journal" id="cit23"><name><surname>Dhakal</surname><given-names>D.</given-names></name>; <name><surname>Han</surname><given-names>J. M.</given-names></name>; <name><surname>Mishra</surname><given-names>R.</given-names></name>; <name><surname>Pandey</surname><given-names>R. P.</given-names></name>; <name><surname>Kim</surname><given-names>T. S.</given-names></name>; <name><surname>Rayamajhi</surname><given-names>V.</given-names></name>; <name><surname>Jung</surname><given-names>H. J.</given-names></name>; <name><surname>Yamaguchi</surname><given-names>T.</given-names></name>; <name><surname>Sohng</surname><given-names>J. K.</given-names></name>
<article-title>Characterization of tailoring steps of nargenicin A1
biosynthesis reveals a novel analogue with anticancer activities</article-title>. <source>ACS Chem. Biol.</source>
<year>2020</year>, <volume>15</volume>, <fpage>1370</fpage>&#x02013;<lpage>1380</lpage>. <pub-id pub-id-type="doi">10.1021/acschembio.9b01034</pub-id>.<pub-id pub-id-type="pmid">32208643</pub-id></mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="journal" id="cit24"><name><surname>Dhakal</surname><given-names>D.</given-names></name>; <name><surname>Rayamajhi</surname><given-names>V.</given-names></name>; <name><surname>Nguyen</surname><given-names>H. T.</given-names></name>; <name><surname>Poudel</surname><given-names>P. B.</given-names></name>; <name><surname>Sohng</surname><given-names>J. K.</given-names></name>
<article-title>Complete
genome sequence of Nocardia sp. strain CS682, a producer of antibacterial
compound nargenicin A1</article-title>. <source>Microbiol. Resour. Announce.</source>
<year>2019</year>, <volume>8</volume>, <elocation-id>e01098</elocation-id><pub-id pub-id-type="doi">10.1128/MRA.01098-19</pub-id>.</mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="patent" id="cit25"><person-group person-group-type="allauthors"><name><surname>Young</surname><given-names>K.</given-names></name>; <name><surname>Olsen</surname><given-names>D.
B.</given-names></name>; <name><surname>Singh</surname><given-names>S.
B.</given-names></name>; <name><surname>Su</surname><given-names>J.</given-names></name>; <name><surname>Wilkening</surname><given-names>R. R.</given-names></name>; <name><surname>Apgar</surname><given-names>J. M.</given-names></name>; <name><surname>Meng</surname><given-names>D.</given-names></name>; <name><surname>Parker</surname><given-names>D.</given-names></name>; <name><surname>Mandal</surname><given-names>M.</given-names></name>; <name><surname>Yang</surname><given-names>L.</given-names></name>; <name><surname>Painter</surname><given-names>R. E.</given-names></name>; <name><surname>Dang</surname><given-names>Q.</given-names></name>; <name><surname>Suzuki</surname><given-names>T.</given-names></name></person-group><article-title>Nargenicin compounds and uses thereof as antibacterial agents</article-title>. United States <patent>US20170305924A1</patent>, <year>2017</year>.</mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="journal" id="cit26"><name><surname>Lorian</surname><given-names>V.</given-names></name>; <name><surname>Finland</surname><given-names>M.</given-names></name>
<article-title>In vitro effect of rifampin on Mycobacteria</article-title>. <source>Appl. Microbiol.</source>
<year>1969</year>, <volume>17</volume>, <fpage>202</fpage>&#x02013;<lpage>207</lpage>. <pub-id pub-id-type="doi">10.1128/am.17.2.202-207.1969</pub-id>.<pub-id pub-id-type="pmid">4975656</pub-id></mixed-citation></ref><ref id="ref27"><mixed-citation publication-type="journal" id="cit27"><name><surname>Yamori</surname><given-names>S.</given-names></name>; <name><surname>Tsukamura</surname><given-names>M.</given-names></name>
<article-title>Paradoxical
effect of tween 80 between the susceptibility
to rifampicin and streptomycin and the susceptibility to ethambutol
and sulfadimethoxine in the Mycobacterium avium-Mycobacterium intracellulare
Complex</article-title>. <source>Microbiol. Immunol.</source>
<year>1991</year>, <volume>35</volume>, <fpage>921</fpage>&#x02013;<lpage>926</lpage>. <pub-id pub-id-type="doi">10.1111/j.1348-0421.1991.tb02031.x</pub-id>.<pub-id pub-id-type="pmid">1779893</pub-id></mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="journal" id="cit28"><name><surname>Ortalo-Magn&#x000e9;</surname><given-names>A.</given-names></name>; <name><surname>Lemassu</surname><given-names>A.</given-names></name>; <name><surname>Laneelle</surname><given-names>M. A.</given-names></name>; <name><surname>Bardou</surname><given-names>F.</given-names></name>; <name><surname>Silve</surname><given-names>G.</given-names></name>; <name><surname>Gounon</surname><given-names>P.</given-names></name>; <name><surname>Marchal</surname><given-names>G.</given-names></name>; <name><surname>Daffe</surname><given-names>M.</given-names></name>
<article-title>Identification of the
surface-exposed lipids on the cell envelopes of <italic>Mycobacterium
tuberculosis</italic> and other mycobacterial species</article-title>. <source>J. Bacteriol.</source>
<year>1996</year>, <volume>178</volume>, <fpage>456</fpage>&#x02013;<lpage>461</lpage>. <pub-id pub-id-type="doi">10.1128/jb.178.2.456-461.1996</pub-id>.<pub-id pub-id-type="pmid">8550466</pub-id></mixed-citation></ref><ref id="ref29"><mixed-citation publication-type="journal" id="cit29"><name><surname>Piddock</surname><given-names>L. J.</given-names></name>; <name><surname>Williams</surname><given-names>K. J.</given-names></name>; <name><surname>Ricci</surname><given-names>V.</given-names></name>
<article-title>Accumulation
of rifampicin by <italic>Mycobacterium aurum</italic>, <italic>Mycobacterium
smegmatis</italic> and <italic>Mycobacterium tuberculosis</italic></article-title>. <source>J. Antimicrob. Chemother.</source>
<year>2000</year>, <volume>45</volume>, <fpage>159</fpage>&#x02013;<lpage>165</lpage>. <pub-id pub-id-type="doi">10.1093/jac/45.2.159</pub-id>.<pub-id pub-id-type="pmid">10660497</pub-id></mixed-citation></ref><ref id="ref30"><mixed-citation publication-type="journal" id="cit30"><name><surname>Tullius</surname><given-names>M. V.</given-names></name>; <name><surname>Nava</surname><given-names>S.</given-names></name>; <name><surname>Horwitz</surname><given-names>M. A.</given-names></name>
<article-title>PPE37 Is essential for <italic>Mycobacterium tuberculosis</italic> heme-iron acquisition
(HIA), and a defective PPE37 in <italic>Mycobacterium bovis</italic> BCG prevents HIA</article-title>. <source>Infect. Immun.</source>
<year>2019</year>, <volume>87</volume>, <elocation-id>e00540</elocation-id><pub-id pub-id-type="doi">10.1128/iai.00540-18</pub-id>.</mixed-citation></ref><ref id="ref31"><mixed-citation publication-type="journal" id="cit31"><name><surname>Kumar</surname><given-names>P.</given-names></name>; <name><surname>Arora</surname><given-names>K.</given-names></name>; <name><surname>Lloyd</surname><given-names>J. R.</given-names></name>; <name><surname>Lee</surname><given-names>I. Y.</given-names></name>; <name><surname>Nair</surname><given-names>V.</given-names></name>; <name><surname>Fischer</surname><given-names>E.</given-names></name>; <name><surname>Boshoff</surname><given-names>H. I.</given-names></name>; <name><surname>Barry</surname><given-names>C. E.</given-names><suffix>3rd</suffix></name>
<article-title>Meropenem inhibits D,D-carboxypeptidase activity in <italic>Mycobacterium tuberculosis</italic></article-title>. <source>Mol. Microbiol.</source>
<year>2012</year>, <volume>86</volume>, <fpage>367</fpage>&#x02013;<lpage>381</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2958.2012.08199.x</pub-id>.<pub-id pub-id-type="pmid">22906310</pub-id></mixed-citation></ref><ref id="ref32"><mixed-citation publication-type="journal" id="cit32"><name><surname>Chengalroyen</surname><given-names>M. D.</given-names></name>; <name><surname>Jordaan</surname><given-names>A.</given-names></name>; <name><surname>Seldon</surname><given-names>R.</given-names></name>; <name><surname>Ioerger</surname><given-names>T.</given-names></name>; <name><surname>Franzblau</surname><given-names>S. G.</given-names></name>; <name><surname>Nasr</surname><given-names>M.</given-names></name>; <name><surname>Warner</surname><given-names>D. F.</given-names></name>; <name><surname>Mizrahi</surname><given-names>V.</given-names></name>
<article-title>Biological profiling
enables rapid mechanistic classification of phenotypic screening hits
and identification of KatG activation-dependent pyridine carboxamide
prodrugs with activity against <italic>Mycobacterium tuberculosis</italic></article-title>. <source>Front Cell. Infect. Microbiol.</source>
<year>2020</year>, <volume>10</volume>, <elocation-id>582416</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2020.582416</pub-id>.<pub-id pub-id-type="pmid">33282750</pub-id></mixed-citation></ref><ref id="ref33"><mixed-citation publication-type="journal" id="cit33"><name><surname>Naran</surname><given-names>K.</given-names></name>; <name><surname>Moosa</surname><given-names>A.</given-names></name>; <name><surname>Barry</surname><given-names>C. E.</given-names></name>; <name><surname>Boshoff</surname><given-names>H. I. M.</given-names></name>; <name><surname>Mizrahi</surname><given-names>V.</given-names></name>; <name><surname>Warner</surname><given-names>D. F.</given-names></name>
<article-title>Bioluminescent reporters for rapid
mechanism of action
assessment in tuberculosis drug discovery</article-title>. <source>Antimicrob.
Agents Chemother.</source>
<year>2016</year>, <volume>60</volume>, <fpage>6748</fpage>&#x02013;<lpage>6757</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.01178-16</pub-id>.<pub-id pub-id-type="pmid">27572410</pub-id></mixed-citation></ref><ref id="ref34"><mixed-citation publication-type="journal" id="cit34"><name><surname>Boshoff</surname><given-names>H. I.</given-names></name>; <name><surname>Myers</surname><given-names>T. G.</given-names></name>; <name><surname>Copp</surname><given-names>B. R.</given-names></name>; <name><surname>McNeil</surname><given-names>M. R.</given-names></name>; <name><surname>Wilson</surname><given-names>M. A.</given-names></name>; <name><surname>Barry</surname><given-names>C. E.</given-names><suffix>3rd</suffix></name>
<article-title>The transcriptional responses of <italic>Mycobacterium tuberculosis</italic> to inhibitors of metabolism:
novel insights into drug mechanisms of action</article-title>. <source>J. Biol. Chem.</source>
<year>2004</year>, <volume>279</volume>, <fpage>40174</fpage>&#x02013;<lpage>40184</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M406796200</pub-id>.<pub-id pub-id-type="pmid">15247240</pub-id></mixed-citation></ref><ref id="ref35"><mixed-citation publication-type="journal" id="cit35"><name><surname>Boshoff</surname><given-names>H. I.</given-names></name>; <name><surname>Reed</surname><given-names>M. B.</given-names></name>; <name><surname>Barry</surname><given-names>C. E.</given-names><suffix>3rd</suffix></name>; <name><surname>Mizrahi</surname><given-names>V.</given-names></name>
<article-title>DnaE2 polymerase
contributes to in vivo survival and the emergence of drug resistance
in <italic>Mycobacterium tuberculosis</italic></article-title>. <source>Cell</source>
<year>2003</year>, <volume>113</volume>, <fpage>183</fpage>&#x02013;<lpage>193</lpage>. <pub-id pub-id-type="doi">10.1016/s0092-8674(03)00270-8</pub-id>.<pub-id pub-id-type="pmid">12705867</pub-id></mixed-citation></ref><ref id="ref36"><mixed-citation publication-type="journal" id="cit36"><name><surname>Warner</surname><given-names>D. F.</given-names></name>; <name><surname>Ndwandwe</surname><given-names>D. E.</given-names></name>; <name><surname>Abrahams</surname><given-names>G. L.</given-names></name>; <name><surname>Kana</surname><given-names>B. D.</given-names></name>; <name><surname>Machowski</surname><given-names>E. E.</given-names></name>; <name><surname>Venclovas</surname><given-names>C.</given-names></name>; <name><surname>Mizrahi</surname><given-names>V.</given-names></name>
<article-title>Essential roles for imuA&#x02019;-
and imuB-encoded accessory factors in DnaE2-dependent mutagenesis
in <italic>Mycobacterium tuberculosis</italic></article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<year>2010</year>, <volume>107</volume>, <fpage>13093</fpage>&#x02013;<lpage>13098</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1002614107</pub-id>.<pub-id pub-id-type="pmid">20615954</pub-id></mixed-citation></ref><ref id="ref37"><mixed-citation publication-type="journal" id="cit37"><name><surname>M&#x000fc;ller</surname><given-names>A. U.</given-names></name>; <name><surname>Imkamp</surname><given-names>F.</given-names></name>; <name><surname>Weber-Ban</surname><given-names>E.</given-names></name>
<article-title>The Mycobacterial LexA/RecA-independent
DNA damage response Is controlled by PafBC and the pup-proteasome
system</article-title>. <source>Cell Rep.</source>
<year>2018</year>, <volume>23</volume>, <fpage>3551</fpage>&#x02013;<lpage>3564</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2018.05.073</pub-id>.<pub-id pub-id-type="pmid">29924998</pub-id></mixed-citation></ref><ref id="ref38"><mixed-citation publication-type="journal" id="cit38"><name><surname>Machowski</surname><given-names>E. E.</given-names></name>; <name><surname>Barichievy</surname><given-names>S.</given-names></name>; <name><surname>Springer</surname><given-names>B.</given-names></name>; <name><surname>Durbach</surname><given-names>S. I.</given-names></name>; <name><surname>Mizrahi</surname><given-names>V.</given-names></name>
<article-title>In vitro analysis
of rates and spectra of mutations in a polymorphic region of the Rv0746
PE_PGRS gene of <italic>Mycobacterium tuberculosis</italic></article-title>. <source>J. Bacteriol.</source>
<year>2007</year>, <volume>189</volume>, <fpage>2190</fpage>&#x02013;<lpage>2195</lpage>. <pub-id pub-id-type="doi">10.1128/JB.01647-06</pub-id>.<pub-id pub-id-type="pmid">17172340</pub-id></mixed-citation></ref><ref id="ref39"><mixed-citation publication-type="journal" id="cit39"><name><surname>de
Wet</surname><given-names>T. J.</given-names></name>; <name><surname>Winkler</surname><given-names>K. R.</given-names></name>; <name><surname>Mhlanga</surname><given-names>M.</given-names></name>; <name><surname>Mizrahi</surname><given-names>V.</given-names></name>; <name><surname>Warner</surname><given-names>D. F.</given-names></name>
<article-title>Arrayed CRISPRi and quantitative imaging describe the
morphotypic landscape of essential mycobacterial genes</article-title>. <source>eLife</source>
<year>2020</year>, <volume>9</volume>, <elocation-id>e60083</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.60083</pub-id>.<pub-id pub-id-type="pmid">33155979</pub-id></mixed-citation></ref><ref id="ref40"><mixed-citation publication-type="journal" id="cit40"><name><surname>Rock</surname><given-names>J. M.</given-names></name>; <name><surname>Hopkins</surname><given-names>F. F.</given-names></name>; <name><surname>Chavez</surname><given-names>A.</given-names></name>; <name><surname>Diallo</surname><given-names>M.</given-names></name>; <name><surname>Chase</surname><given-names>M. R.</given-names></name>; <name><surname>Gerrick</surname><given-names>E. R.</given-names></name>; <name><surname>Pritchard</surname><given-names>J. R.</given-names></name>; <name><surname>Church</surname><given-names>G. M.</given-names></name>; <name><surname>Rubin</surname><given-names>E. J.</given-names></name>; <name><surname>Sassetti</surname><given-names>C. M.</given-names></name>; <name><surname>Schnappinger</surname><given-names>D.</given-names></name>; <name><surname>Fortune</surname><given-names>S. M.</given-names></name>
<article-title>Programmable transcriptional
repression in mycobacteria using an orthogonal CRISPR interference
platform</article-title>. <source>Nat. Microbiol.</source>
<year>2017</year>, <volume>2</volume>, <elocation-id>16274</elocation-id><pub-id pub-id-type="doi">10.1038/nmicrobiol.2016.274</pub-id>.<pub-id pub-id-type="pmid">28165460</pub-id></mixed-citation></ref><ref id="ref41"><mixed-citation publication-type="journal" id="cit41"><name><surname>Rock</surname><given-names>J. M.</given-names></name>; <name><surname>Lang</surname><given-names>U. F.</given-names></name>; <name><surname>Chase</surname><given-names>M. R.</given-names></name>; <name><surname>Ford</surname><given-names>C. B.</given-names></name>; <name><surname>Gerrick</surname><given-names>E. R.</given-names></name>; <name><surname>Gawande</surname><given-names>R.</given-names></name>; <name><surname>Coscolla</surname><given-names>M.</given-names></name>; <name><surname>Gagneux</surname><given-names>S.</given-names></name>; <name><surname>Fortune</surname><given-names>S. M.</given-names></name>; <name><surname>Lamers</surname><given-names>M. H.</given-names></name>
<article-title>DNA replication fidelity in <italic>Mycobacterium
tuberculosis</italic> is mediated by an ancestral prokaryotic
proofreader</article-title>. <source>Nat. Genet.</source>
<year>2015</year>, <volume>47</volume>, <fpage>677</fpage>&#x02013;<lpage>681</lpage>. <pub-id pub-id-type="doi">10.1038/ng.3269</pub-id>.<pub-id pub-id-type="pmid">25894501</pub-id></mixed-citation></ref><ref id="ref42"><mixed-citation publication-type="journal" id="cit42"><name><surname>Ba&#x000f1;os-Mateos</surname><given-names>S.</given-names></name>; <name><surname>van Roon</surname><given-names>A.-M. M.</given-names></name>; <name><surname>Lang</surname><given-names>U. F.</given-names></name>; <name><surname>Maslen</surname><given-names>S. L.</given-names></name>; <name><surname>Skehel</surname><given-names>J. M.</given-names></name>; <name><surname>Lamers</surname><given-names>M. H.</given-names></name>
<article-title>High-fidelity DNA replication in <italic>Mycobacterium
tuberculosis</italic> relies on a trinuclear zinc center</article-title>. <source>Nat. Commun.</source>
<year>2017</year>, <volume>8</volume>, <elocation-id>855</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-017-00886-w</pub-id>.<pub-id pub-id-type="pmid">29021523</pub-id></mixed-citation></ref><ref id="ref43"><mixed-citation publication-type="journal" id="cit43"><name><surname>Fernandez-Leiro</surname><given-names>R.</given-names></name>; <name><surname>Conrad</surname><given-names>J.</given-names></name>; <name><surname>Scheres</surname><given-names>S. H.</given-names></name>; <name><surname>Lamers</surname><given-names>M. H.</given-names></name>
<article-title>cryo-EM structures
of the E. coli replicative DNA polymerase reveal its dynamic interactions
with the DNA sliding clamp, exonuclease and tau</article-title>. <source>eLife</source>
<year>2015</year>, <volume>4</volume>, <elocation-id>e11134</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.11134</pub-id>.<pub-id pub-id-type="pmid">26499492</pub-id></mixed-citation></ref><ref id="ref44"><mixed-citation publication-type="journal" id="cit44a"><label>a</label><name><surname>Evans</surname><given-names>R. J.</given-names></name>; <name><surname>Davies</surname><given-names>D. R.</given-names></name>; <name><surname>Bullard</surname><given-names>J. M.</given-names></name>; <name><surname>Christensen</surname><given-names>J.</given-names></name>; <name><surname>Green</surname><given-names>L. S.</given-names></name>; <name><surname>Guiles</surname><given-names>J. W.</given-names></name>; <name><surname>Pata</surname><given-names>J. D.</given-names></name>; <name><surname>Ribble</surname><given-names>W. K.</given-names></name>; <name><surname>Janjic</surname><given-names>N.</given-names></name>; <name><surname>Jarvis</surname><given-names>T. C.</given-names></name>
<article-title>Structure of PolC
reveals unique DNA binding and fidelity determinants</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<year>2008</year>, <volume>105</volume>, <fpage>20695</fpage>&#x02013;<lpage>20700</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0809989106</pub-id>.<pub-id pub-id-type="pmid">19106298</pub-id></mixed-citation><mixed-citation publication-type="journal" id="cit44b"><label> b</label><name><surname>Wing</surname><given-names>R. A.</given-names></name>; <name><surname>Bailey</surname><given-names>S.</given-names></name>; <name><surname>Steitz</surname><given-names>T. A.</given-names></name>
<article-title>Insights into the
replisome from the structure of a ternary complex of the DNA polymerase
III alpha-subunit</article-title>. <source>J. Mol. Biol.</source>
<year>2008</year>, <volume>382</volume>, <fpage>859</fpage>&#x02013;<lpage>869</lpage>. <pub-id pub-id-type="doi">10.1016/j.jmb.2008.07.058</pub-id>.<pub-id pub-id-type="pmid">18691598</pub-id></mixed-citation></ref><ref id="ref45"><mixed-citation publication-type="journal" id="cit45"><name><surname>Brundret</surname><given-names>K. M.</given-names></name>; <name><surname>Dalziel</surname><given-names>W.</given-names></name>; <name><surname>Hesp</surname><given-names>B.</given-names></name>; <name><surname>Jarvis</surname><given-names>J. A. J.</given-names></name>; <name><surname>Neidle</surname><given-names>S.</given-names></name>
<article-title>X-Ray crystallographic
determination of the structure of the antibiotic aphidicolin: a tetracyclic
diterpenoid containing a new ring system</article-title>. <source>J.
Chem. Soc., Chem. Commun.</source>
<year>1972</year>, <fpage>1027</fpage>&#x02013;<lpage>1028</lpage>. <pub-id pub-id-type="doi">10.1039/C39720001027</pub-id>.</mixed-citation></ref><ref id="ref46"><mixed-citation publication-type="journal" id="cit46"><name><surname>Inoue</surname><given-names>R.</given-names></name>; <name><surname>Kaito</surname><given-names>C.</given-names></name>; <name><surname>Tanabe</surname><given-names>M.</given-names></name>; <name><surname>Kamura</surname><given-names>K.</given-names></name>; <name><surname>Akimitsu</surname><given-names>N.</given-names></name>; <name><surname>Sekimizu</surname><given-names>K.</given-names></name>
<article-title>Genetic identification
of two distinct DNA polymerases,
DnaE and PolC, that are essential for chromosomal DNA replication
in Staphylococcus aureus</article-title>. <source>Mol. Genet. Genomics</source>
<year>2001</year>, <volume>266</volume>, <fpage>564</fpage>&#x02013;<lpage>571</lpage>. <pub-id pub-id-type="doi">10.1007/s004380100564</pub-id>.<pub-id pub-id-type="pmid">11810227</pub-id></mixed-citation></ref><ref id="ref47"><mixed-citation publication-type="journal" id="cit47"><name><surname>Sinha</surname><given-names>K. M.</given-names></name>; <name><surname>Unciuleac</surname><given-names>M. C.</given-names></name>; <name><surname>Glickman</surname><given-names>M. S.</given-names></name>; <name><surname>Shuman</surname><given-names>S.</given-names></name>
<article-title>AdnAB: a new
DSB-resecting
motor-nuclease from mycobacteria</article-title>. <source>Genes Dev.</source>
<year>2009</year>, <volume>23</volume>, <fpage>1423</fpage>&#x02013;<lpage>1437</lpage>. <pub-id pub-id-type="doi">10.1101/gad.1805709</pub-id>.<pub-id pub-id-type="pmid">19470566</pub-id></mixed-citation></ref><ref id="ref48"><mixed-citation publication-type="journal" id="cit48"><name><surname>Chauhan</surname><given-names>A.</given-names></name>; <name><surname>Lofton</surname><given-names>H.</given-names></name>; <name><surname>Maloney</surname><given-names>E.</given-names></name>; <name><surname>Moore</surname><given-names>J.</given-names></name>; <name><surname>Fol</surname><given-names>M.</given-names></name>; <name><surname>Madiraju</surname><given-names>M. V.</given-names></name>; <name><surname>Rajagopalan</surname><given-names>M.</given-names></name>
<article-title>Interference of <italic>Mycobacterium
tuberculosis</italic> cell division by Rv2719c, a cell wall
hydrolase</article-title>. <source>Mol. Microbiol.</source>
<year>2006</year>, <volume>62</volume>, <fpage>132</fpage>&#x02013;<lpage>147</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2958.2006.05333.x</pub-id>.<pub-id pub-id-type="pmid">16942606</pub-id></mixed-citation></ref><ref id="ref49"><mixed-citation publication-type="journal" id="cit49"><name><surname>Bush</surname><given-names>N. G.</given-names></name>; <name><surname>Diez-Santos</surname><given-names>I.</given-names></name>; <name><surname>Abbott</surname><given-names>L. R.</given-names></name>; <name><surname>Maxwell</surname><given-names>A.</given-names></name>
<article-title>Quinolones: Mechanism,
lethality and their contributions to antibiotic resistance</article-title>. <source>Molecules</source>
<year>2020</year>, <volume>25</volume>, <fpage>5662</fpage><pub-id pub-id-type="doi">10.3390/molecules25235662</pub-id>.</mixed-citation></ref><ref id="ref50"><mixed-citation publication-type="journal" id="cit50"><name><surname>Gillespie</surname><given-names>S. H.</given-names></name>; <name><surname>Basu</surname><given-names>S.</given-names></name>; <name><surname>Dickens</surname><given-names>A. L.</given-names></name>; <name><surname>O&#x02019;Sullivan</surname><given-names>D. M.</given-names></name>; <name><surname>McHugh</surname><given-names>T. D.</given-names></name>
<article-title>Effect of subinhibitory concentrations
of ciprofloxacin
on Mycobacterium fortuitum mutation rates</article-title>. <source>J.
Antimicrob. Chemother.</source>
<year>2005</year>, <volume>56</volume>, <fpage>344</fpage>&#x02013;<lpage>348</lpage>. <pub-id pub-id-type="doi">10.1093/jac/dki191</pub-id>.<pub-id pub-id-type="pmid">15956099</pub-id></mixed-citation></ref><ref id="ref51"><mixed-citation publication-type="journal" id="cit51"><name><surname>Gupta</surname><given-names>S.</given-names></name>; <name><surname>Banerjee</surname><given-names>S. K.</given-names></name>; <name><surname>Chatterjee</surname><given-names>A.</given-names></name>; <name><surname>Sharma</surname><given-names>A. K.</given-names></name>; <name><surname>Kundu</surname><given-names>M.</given-names></name>; <name><surname>Basu</surname><given-names>J.</given-names></name>
<article-title>Essential protein SepF
of mycobacteria interacts with FtsZ and MurG
to regulate cell growth and division</article-title>. <source>Microbiology</source>
<year>2015</year>, <volume>161</volume>, <fpage>1627</fpage>&#x02013;<lpage>1638</lpage>. <pub-id pub-id-type="doi">10.1099/mic.0.000108</pub-id>.<pub-id pub-id-type="pmid">25971440</pub-id></mixed-citation></ref><ref id="ref52"><mixed-citation publication-type="journal" id="cit52"><name><surname>Bush</surname><given-names>M. J.</given-names></name>
<article-title>The actinobacterial
WhiB-like (Wbl) family of transcription factors</article-title>. <source>Mol. Microbiol.</source>
<year>2018</year>, <volume>110</volume>, <fpage>663</fpage>&#x02013;<lpage>676</lpage>. <pub-id pub-id-type="doi">10.1111/mmi.14117</pub-id>.<pub-id pub-id-type="pmid">30179278</pub-id></mixed-citation></ref><ref id="ref53"><mixed-citation publication-type="journal" id="cit53"><name><surname>Adefisayo</surname><given-names>O. O.</given-names></name>; <name><surname>Dupuy</surname><given-names>P.</given-names></name>; <name><surname>Nautiyal</surname><given-names>A.</given-names></name>; <name><surname>Bean</surname><given-names>J. M.</given-names></name>; <name><surname>Glickman</surname><given-names>M. S.</given-names></name>
<article-title>Division
of labor between SOS and PafBC in mycobacterial DNA repair and mutagenesis</article-title>. <source>Nucleic Acids Res.</source>
<year>2021</year>, <volume>49</volume>, <fpage>12805</fpage>&#x02013;<lpage>12819</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkab1169</pub-id>.<pub-id pub-id-type="pmid">34871411</pub-id></mixed-citation></ref><ref id="ref54"><mixed-citation publication-type="journal" id="cit54"><name><surname>Burby</surname><given-names>P. E.</given-names></name>; <name><surname>Simmons</surname><given-names>L. A.</given-names></name>
<article-title>Regulation of cell division in bacteria by monitoring
genome integrity and DNA replication status</article-title>. <source>J. Bacteriol.</source>
<year>2020</year>, <volume>202</volume>, <elocation-id>e00408</elocation-id><pub-id pub-id-type="doi">10.1128/JB.00408-19</pub-id>.<pub-id pub-id-type="pmid">31548275</pub-id></mixed-citation></ref><ref id="ref55"><mixed-citation publication-type="journal" id="cit55"><name><surname>Jackson</surname><given-names>M.</given-names></name>; <name><surname>Raynaud</surname><given-names>C.</given-names></name>; <name><surname>Lan&#x000e9;elle</surname><given-names>M. A.</given-names></name>; <name><surname>Guilhot</surname><given-names>C.</given-names></name>; <name><surname>Laurent-Winter</surname><given-names>C.</given-names></name>; <name><surname>Ensergueix</surname><given-names>D.</given-names></name>; <name><surname>Gicquel</surname><given-names>B.</given-names></name>; <name><surname>Daff&#x000e9;</surname><given-names>M.</given-names></name>
<article-title>Inactivation
of the antigen 85C gene profoundly affects the mycolate content and
alters the permeability of the <italic>Mycobacterium tuberculosis</italic> cell envelope</article-title>. <source>Mol. Microbiol.</source>
<year>1999</year>, <volume>31</volume>, <fpage>1573</fpage>&#x02013;<lpage>1587</lpage>. <pub-id pub-id-type="doi">10.1046/j.1365-2958.1999.01310.x</pub-id>.<pub-id pub-id-type="pmid">10200974</pub-id></mixed-citation></ref><ref id="ref56"><mixed-citation publication-type="journal" id="cit56"><name><surname>Ioerger</surname><given-names>T. R.</given-names></name>; <name><surname>Feng</surname><given-names>Y.</given-names></name>; <name><surname>Ganesula</surname><given-names>K.</given-names></name>; <name><surname>Chen</surname><given-names>X.</given-names></name>; <name><surname>Dobos</surname><given-names>K. M.</given-names></name>; <name><surname>Fortune</surname><given-names>S.</given-names></name>; <name><surname>Jacobs</surname><given-names>W. R.</given-names><suffix>Jr</suffix></name>; <name><surname>Mizrahi</surname><given-names>V.</given-names></name>; <name><surname>Parish</surname><given-names>T.</given-names></name>; <name><surname>Rubin</surname><given-names>E.</given-names></name>; <name><surname>Sassetti</surname><given-names>C.</given-names></name>; <name><surname>Sacchettini</surname><given-names>J. C.</given-names></name>
<article-title>Variation
among genome sequences of H37Rv strains of <italic>Mycobacterium
tuberculosis</italic> from multiple laboratories</article-title>. <source>J. Bacteriol.</source>
<year>2010</year>, <volume>192</volume>, <fpage>3645</fpage>&#x02013;<lpage>3653</lpage>. <pub-id pub-id-type="doi">10.1128/JB.00166-10</pub-id>.<pub-id pub-id-type="pmid">20472797</pub-id></mixed-citation></ref><ref id="ref57"><mixed-citation publication-type="journal" id="cit57"><name><surname>Snapper</surname><given-names>S. B.</given-names></name>; <name><surname>Melton</surname><given-names>R. E.</given-names></name>; <name><surname>Mustafa</surname><given-names>S.</given-names></name>; <name><surname>Kieser</surname><given-names>T.</given-names></name>; <name><surname>Jacobs</surname><given-names>W. R.</given-names><suffix>Jr.</suffix></name>
<article-title>Isolation and characterization of efficient plasmid
transformation mutants of <italic>Mycobacterium smegmatis</italic></article-title>. <source>Mol. Microbiol.</source>
<year>1990</year>, <volume>4</volume>, <fpage>1911</fpage>&#x02013;<lpage>1919</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2958.1990.tb02040.x</pub-id>.<pub-id pub-id-type="pmid">2082148</pub-id></mixed-citation></ref><ref id="ref58"><mixed-citation publication-type="journal" id="cit58"><name><surname>Shamputa</surname><given-names>I. C.</given-names></name>; <name><surname>Lee</surname><given-names>J.</given-names></name>; <name><surname>Allix-Beguec</surname><given-names>C.</given-names></name>; <name><surname>Cho</surname><given-names>E. J.</given-names></name>; <name><surname>Lee</surname><given-names>J. I.</given-names></name>; <name><surname>Rajan</surname><given-names>V.</given-names></name>; <name><surname>Lee</surname><given-names>E. G.</given-names></name>; <name><surname>Min</surname><given-names>J. H.</given-names></name>; <name><surname>Carroll</surname><given-names>M. W.</given-names></name>; <name><surname>Goldfeder</surname><given-names>L. C.</given-names></name>; <name><surname>Kim</surname><given-names>J. H.</given-names></name>; <name><surname>Kang</surname><given-names>H. S.</given-names></name>; <name><surname>Hwang</surname><given-names>S.</given-names></name>; <name><surname>Eum</surname><given-names>S. Y.</given-names></name>; <name><surname>Park</surname><given-names>S. K.</given-names></name>; <name><surname>Lee</surname><given-names>H.</given-names></name>; <name><surname>Supply</surname><given-names>P.</given-names></name>; <name><surname>Cho</surname><given-names>S. N.</given-names></name>; <name><surname>Via</surname><given-names>L. E.</given-names></name>; <name><surname>Barry</surname><given-names>C. E.</given-names><suffix>3rd</suffix></name>
<article-title>Genetic diversity
of <italic>Mycobacterium tuberculosis</italic> isolates
from a tertiary care tuberculosis hospital in South Korea</article-title>. <source>J. Clin. Microbiol.</source>
<year>2010</year>, <volume>48</volume>, <fpage>387</fpage>&#x02013;<lpage>394</lpage>. <pub-id pub-id-type="doi">10.1128/JCM.02167-09</pub-id>.<pub-id pub-id-type="pmid">20018816</pub-id></mixed-citation></ref><ref id="ref59"><mixed-citation publication-type="journal" id="cit59"><name><surname>Abrahams</surname><given-names>G. L.</given-names></name>; <name><surname>Kumar</surname><given-names>A.</given-names></name>; <name><surname>Savvi</surname><given-names>S.</given-names></name>; <name><surname>Hung</surname><given-names>A. W.</given-names></name>; <name><surname>Wen</surname><given-names>S.</given-names></name>; <name><surname>Abell</surname><given-names>C.</given-names></name>; <name><surname>Barry</surname><given-names>C. E.</given-names><suffix>3rd</suffix></name>; <name><surname>Sherman</surname><given-names>D. R.</given-names></name>; <name><surname>Boshoff</surname><given-names>H. I.</given-names></name>; <name><surname>Mizrahi</surname><given-names>V.</given-names></name>
<article-title>Pathway-selective
sensitization of <italic>Mycobacterium tuberculosis</italic> for target-based whole-cell
screening</article-title>. <source>Chem. Biol.</source>
<year>2012</year>, <volume>19</volume>, <fpage>844</fpage>&#x02013;<lpage>854</lpage>. <pub-id pub-id-type="doi">10.1016/j.chembiol.2012.05.020</pub-id>.<pub-id pub-id-type="pmid">22840772</pub-id></mixed-citation></ref><ref id="ref60"><mixed-citation publication-type="journal" id="cit60"><name><surname>Valway</surname><given-names>S. E.</given-names></name>; <name><surname>Sanchez</surname><given-names>M. P.</given-names></name>; <name><surname>Shinnick</surname><given-names>T. F.</given-names></name>; <name><surname>Orme</surname><given-names>I.</given-names></name>; <name><surname>Agerton</surname><given-names>T.</given-names></name>; <name><surname>Hoy</surname><given-names>D.</given-names></name>; <name><surname>Jones</surname><given-names>J. S.</given-names></name>; <name><surname>Westmoreland</surname><given-names>H.</given-names></name>; <name><surname>Onorato</surname><given-names>I. M.</given-names></name>
<article-title>An outbreak involving
extensive transmission of a virulent strain of <italic>Mycobacterium
tuberculosis</italic></article-title>. <source>N. Engl. J. Med.</source>
<year>1998</year>, <volume>338</volume>, <fpage>633</fpage>&#x02013;<lpage>639</lpage>. <pub-id pub-id-type="doi">10.1056/NEJM199803053381001</pub-id>.<pub-id pub-id-type="pmid">9486991</pub-id></mixed-citation></ref><ref id="ref61"><mixed-citation publication-type="journal" id="cit61"><name><surname>Manca</surname><given-names>C.</given-names></name>; <name><surname>Tsenova</surname><given-names>L.</given-names></name>; <name><surname>Bergtold</surname><given-names>A.</given-names></name>; <name><surname>Freeman</surname><given-names>S.</given-names></name>; <name><surname>Tovey</surname><given-names>M.</given-names></name>; <name><surname>Musser</surname><given-names>J. M.</given-names></name>; <name><surname>Barry</surname><given-names>C. E.</given-names><suffix>3rd</suffix></name>; <name><surname>Freedman</surname><given-names>V. H.</given-names></name>; <name><surname>Kaplan</surname><given-names>G.</given-names></name>
<article-title>Virulence of a <italic>Mycobacterium tuberculosis</italic> clinical isolate in mice
is determined by failure to induce Th1
type immunity and is associated with induction of IFN-alpha /beta</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<year>2001</year>, <volume>98</volume>, <fpage>5752</fpage>&#x02013;<lpage>5757</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.091096998</pub-id>.<pub-id pub-id-type="pmid">11320211</pub-id></mixed-citation></ref><ref id="ref62"><mixed-citation publication-type="journal" id="cit62"><name><surname>Barrow</surname><given-names>E. W.</given-names></name>; <name><surname>Westbrook</surname><given-names>L.</given-names></name>; <name><surname>Bansal</surname><given-names>N.</given-names></name>; <name><surname>Suling</surname><given-names>W. J.</given-names></name>; <name><surname>Maddry</surname><given-names>J. A.</given-names></name>; <name><surname>Parker</surname><given-names>W. B.</given-names></name>; <name><surname>Barrow</surname><given-names>W. W.</given-names></name>
<article-title>Antimycobacterial activity of 2-methyl-adenosine</article-title>. <source>J. Antimicrob. Chemother.</source>
<year>2003</year>, <volume>52</volume>, <fpage>801</fpage>&#x02013;<lpage>808</lpage>. <pub-id pub-id-type="doi">10.1093/jac/dkg444</pub-id>.<pub-id pub-id-type="pmid">14563890</pub-id></mixed-citation></ref><ref id="ref63"><mixed-citation publication-type="journal" id="cit63"><name><surname>Cotsonas
King</surname><given-names>A.</given-names></name>; <name><surname>Wu</surname><given-names>L.</given-names></name>
<article-title>Macromolecular synthesis and membrane perturbation
assays for mechanisms of action studies of antimicrobial agents</article-title>. <source>Curr. Protoc. Pharmacol.</source>
<year>2009</year>, <volume>47</volume>, <fpage>13A-7</fpage><pub-id pub-id-type="doi">10.1002/0471141755.ph13a07s47</pub-id>.</mixed-citation></ref><ref id="ref64"><mixed-citation publication-type="journal" id="cit64"><name><surname>Schindelin</surname><given-names>J.</given-names></name>; <name><surname>Arganda-Carreras</surname><given-names>I.</given-names></name>; <name><surname>Frise</surname><given-names>E.</given-names></name>; <name><surname>Kaynig</surname><given-names>V.</given-names></name>; <name><surname>Longair</surname><given-names>M.</given-names></name>; <name><surname>Pietzsch</surname><given-names>T.</given-names></name>; <name><surname>Preibisch</surname><given-names>S.</given-names></name>; <name><surname>Rueden</surname><given-names>C.</given-names></name>; <name><surname>Saalfeld</surname><given-names>S.</given-names></name>; <name><surname>Schmid</surname><given-names>B.</given-names></name>; <name><surname>Tinevez</surname><given-names>J.-Y.</given-names></name>; <name><surname>White</surname><given-names>D. J.</given-names></name>; <name><surname>Hartenstein</surname><given-names>V.</given-names></name>; <name><surname>Eliceiri</surname><given-names>K.</given-names></name>; <name><surname>Tomancak</surname><given-names>P.</given-names></name>; <name><surname>Cardona</surname><given-names>A.</given-names></name>
<article-title>Fiji: an open-source
platform for biological-image analysis</article-title>. <source>Nat.
Methods</source>
<year>2012</year>, <volume>9</volume>, <fpage>676</fpage>&#x02013;<lpage>682</lpage>. <pub-id pub-id-type="doi">10.1038/nmeth.2019</pub-id>.<pub-id pub-id-type="pmid">22743772</pub-id></mixed-citation></ref><ref id="ref65"><mixed-citation publication-type="journal" id="cit65"><name><surname>Ducret</surname><given-names>A.</given-names></name>; <name><surname>Quardokus</surname><given-names>E. M.</given-names></name>; <name><surname>Brun</surname><given-names>Y. V.</given-names></name>
<article-title>MicrobeJ, a tool for high throughput
bacterial cell detection and quantitative analysis</article-title>. <source>Nat. Microbiol.</source>
<year>2016</year>, <volume>1</volume>, <fpage>16077</fpage><pub-id pub-id-type="doi">10.1038/nmicrobiol.2016.77</pub-id>.<pub-id pub-id-type="pmid">27572972</pub-id></mixed-citation></ref><ref id="ref66"><mixed-citation publication-type="book" id="cit66"><collab>R Core Team</collab>. <source>R: A Language and
Environment for Statistical
Computing</source>; <publisher-name>R Foundation for Statistical Computing,
RStudio Team</publisher-name>. <italic>RStudio: Integrated development
for R; PBC</italic>, <year>2020</year>.</mixed-citation></ref><ref id="ref67"><mixed-citation publication-type="weblink" id="cit67"><article-title>FastQC:
A quality control tool for high throughput sequence data</article-title>. <year>2010</year>, <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.bioinformatics.babraham.ac.uk/projects/fastqc/">http://www.bioinformatics.babraham.ac.uk/projects/fastqc/</uri>.</mixed-citation></ref><ref id="ref68"><mixed-citation publication-type="journal" id="cit68"><name><surname>Wang</surname><given-names>L.</given-names></name>; <name><surname>Nie</surname><given-names>J.</given-names></name>; <name><surname>Sicotte</surname><given-names>H.</given-names></name>; <name><surname>Li</surname><given-names>Y.</given-names></name>; <name><surname>Eckel-Passow</surname><given-names>J. E.</given-names></name>; <name><surname>Dasari</surname><given-names>S.</given-names></name>; <name><surname>Vedell</surname><given-names>P. T.</given-names></name>; <name><surname>Barman</surname><given-names>P.</given-names></name>; <name><surname>Wang</surname><given-names>L.</given-names></name>; <name><surname>Weinshiboum</surname><given-names>R.</given-names></name>; <name><surname>Jen</surname><given-names>J.</given-names></name>; <name><surname>Huang</surname><given-names>H.</given-names></name>; <name><surname>Kohli</surname><given-names>M.</given-names></name>; <name><surname>Kocher</surname><given-names>J.-P. A.</given-names></name>
<article-title>Measure transcript
integrity using RNA-seq data</article-title>. <source>BMC Bioinf.</source>
<year>2016</year>, <volume>17</volume>, <elocation-id>58</elocation-id><pub-id pub-id-type="doi">10.1186/s12859-016-0922-z</pub-id>.</mixed-citation></ref><ref id="ref69"><mixed-citation publication-type="journal" id="cit69"><name><surname>Sayols</surname><given-names>S.</given-names></name>; <name><surname>Scherzinger</surname><given-names>D.</given-names></name>; <name><surname>Klein</surname><given-names>H.</given-names></name>
<article-title>dupRadar: a Bioconductor
package
for the assessment of PCR artifacts in RNA-Seq data</article-title>. <source>BMC Bioinf.</source>
<year>2016</year>, <volume>17</volume>, <elocation-id>428</elocation-id><pub-id pub-id-type="doi">10.1186/s12859-016-1276-2</pub-id>.</mixed-citation></ref><ref id="ref70"><mixed-citation publication-type="journal" id="cit70"><name><surname>Ewels</surname><given-names>P.</given-names></name>; <name><surname>Magnusson</surname><given-names>M.</given-names></name>; <name><surname>Lundin</surname><given-names>S.</given-names></name>; <name><surname>K&#x000e4;ller</surname><given-names>M.</given-names></name>
<article-title>MultiQC: summarize
analysis results for multiple tools and samples in a single report</article-title>. <source>Bioinformatics</source>
<year>2016</year>, <volume>32</volume>, <fpage>3047</fpage>&#x02013;<lpage>3048</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/btw354</pub-id>.<pub-id pub-id-type="pmid">27312411</pub-id></mixed-citation></ref><ref id="ref71"><mixed-citation publication-type="journal" id="cit71"><name><surname>Patro</surname><given-names>R.</given-names></name>; <name><surname>Duggal</surname><given-names>G.</given-names></name>; <name><surname>Love</surname><given-names>M. I.</given-names></name>; <name><surname>Irizarry</surname><given-names>R. A.</given-names></name>; <name><surname>Kingsford</surname><given-names>C.</given-names></name>
<article-title>Salmon provides
fast and bias-aware quantification of transcript expression</article-title>. <source>Nat. Methods</source>
<year>2017</year>, <volume>14</volume>, <fpage>417</fpage>&#x02013;<lpage>419</lpage>. <pub-id pub-id-type="doi">10.1038/nmeth.4197</pub-id>.<pub-id pub-id-type="pmid">28263959</pub-id></mixed-citation></ref><ref id="ref72"><mixed-citation publication-type="journal" id="cit72"><name><surname>Love</surname><given-names>M. I.</given-names></name>; <name><surname>Huber</surname><given-names>W.</given-names></name>; <name><surname>Anders</surname><given-names>S.</given-names></name>
<article-title>Moderated
estimation of fold change
and dispersion for RNA-seq data with DESeq. 2</article-title>. <source>Genome Biol.</source>
<year>2014</year>, <volume>15</volume>, <elocation-id>550</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id>.<pub-id pub-id-type="pmid">25516281</pub-id></mixed-citation></ref><ref id="ref73"><mixed-citation publication-type="journal" id="cit73"><name><surname>Szklarczyk</surname><given-names>D.</given-names></name>; <name><surname>Gable</surname><given-names>A. L.</given-names></name>; <name><surname>Lyon</surname><given-names>D.</given-names></name>; <name><surname>Junge</surname><given-names>A.</given-names></name>; <name><surname>Wyder</surname><given-names>S.</given-names></name>; <name><surname>Huerta-Cepas</surname><given-names>J.</given-names></name>; <name><surname>Simonovic</surname><given-names>M.</given-names></name>; <name><surname>Doncheva</surname><given-names>N. T.</given-names></name>; <name><surname>Morris</surname><given-names>J. H.</given-names></name>; <name><surname>Bork</surname><given-names>P.</given-names></name>; <name><surname>Jensen</surname><given-names>L. J.</given-names></name>; <name><surname>von Mering</surname><given-names>C.</given-names></name>
<article-title>STRING v11:
protein&#x02013;protein association networks with increased coverage,
supporting functional discovery in genome-wide experimental datasets</article-title>. <source>Nucleic Acids Res.</source>
<year>2019</year>, <volume>47</volume>, <fpage>D607</fpage>&#x02013;<lpage>D613</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gky1131</pub-id>.<pub-id pub-id-type="pmid">30476243</pub-id></mixed-citation></ref><ref id="ref74"><mixed-citation publication-type="journal" id="cit74"><name><surname>Kolbe</surname><given-names>K.</given-names></name>; <name><surname>Bell</surname><given-names>A. C.</given-names></name>; <name><surname>Prosser</surname><given-names>G. A.</given-names></name>; <name><surname>Assmann</surname><given-names>M.</given-names></name>; <name><surname>Yang</surname><given-names>H.-J.</given-names></name>; <name><surname>Forbes</surname><given-names>H. E.</given-names></name>; <name><surname>Gallucci</surname><given-names>S.</given-names></name>; <name><surname>Mayer-Barber</surname><given-names>K. D.</given-names></name>; <name><surname>Boshoff</surname><given-names>H. I.</given-names></name>; <name><surname>Barry</surname><given-names>C. E.</given-names><suffix>3rd</suffix></name>
<article-title>Development and
optimization of chromosomally-integrated fluorescent <italic>Mycobacterium tuberculosis</italic> reporter constructs</article-title>. <source>Front. Microbiol.</source>
<year>2020</year>, <volume>11</volume>, <elocation-id>591866</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2020.591866</pub-id>.<pub-id pub-id-type="pmid">33362741</pub-id></mixed-citation></ref><ref id="ref75"><mixed-citation publication-type="journal" id="cit75"><name><surname>Toste
R&#x000ea;go</surname><given-names>A.</given-names></name>; <name><surname>Holding</surname><given-names>A. N.</given-names></name>; <name><surname>Kent</surname><given-names>H.</given-names></name>; <name><surname>Lamers</surname><given-names>M. H.</given-names></name>
<article-title>Architecture
of the Pol III-clamp-exonuclease complex reveals key roles of the
exonuclease subunit in processive DNA synthesis and repair</article-title>. <source>EMBO J.</source>
<year>2013</year>, <volume>32</volume>, <fpage>1334</fpage>&#x02013;<lpage>1343</lpage>. <pub-id pub-id-type="doi">10.1038/emboj.2013.68</pub-id>.<pub-id pub-id-type="pmid">23549287</pub-id></mixed-citation></ref><ref id="ref76"><mixed-citation publication-type="journal" id="cit76"><name><surname>Zivanov</surname><given-names>J.</given-names></name>; <name><surname>Nakane</surname><given-names>T.</given-names></name>; <name><surname>Forsberg</surname><given-names>B. O.</given-names></name>; <name><surname>Kimanius</surname><given-names>D.</given-names></name>; <name><surname>Hagen</surname><given-names>W. J.</given-names></name>; <name><surname>Lindahl</surname><given-names>E.</given-names></name>; <name><surname>Scheres</surname><given-names>S. H.</given-names></name>
<article-title>New tools
for automated high-resolution
cryo-EM structure determination in RELION-3</article-title>. <source>eLife</source>
<year>2018</year>, <volume>7</volume>, <elocation-id>e42166</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.42166</pub-id>.<pub-id pub-id-type="pmid">30412051</pub-id></mixed-citation></ref><ref id="ref77"><mixed-citation publication-type="journal" id="cit77"><name><surname>Zhang</surname><given-names>K.</given-names></name>
<article-title>Gctf: Real-time
CTF determination and correction</article-title>. <source>J. Struct.
Biol.</source>
<year>2016</year>, <volume>193</volume>, <fpage>1</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1016/j.jsb.2015.11.003</pub-id>.<pub-id pub-id-type="pmid">26592709</pub-id></mixed-citation></ref><ref id="ref78"><mixed-citation publication-type="journal" id="cit78"><name><surname>Subramaniya</surname><given-names>S. R. M.
V.</given-names></name>; <name><surname>Terashi</surname><given-names>G.</given-names></name>; <name><surname>Kihara</surname><given-names>D.</given-names></name>
<article-title>Super-Resolution cryo-EM Maps with
3D deep generative networks</article-title>. <source>bioRxiv</source>
<year>2021</year>, <pub-id pub-id-type="doi">10.1101/2021.01.12.426430</pub-id>.</mixed-citation></ref><ref id="ref79"><mixed-citation publication-type="journal" id="cit79"><name><surname>Emsley</surname><given-names>P.</given-names></name>; <name><surname>Lohkamp</surname><given-names>B.</given-names></name>; <name><surname>Scott</surname><given-names>W. G.</given-names></name>; <name><surname>Cowtan</surname><given-names>K.</given-names></name>
<article-title>Features and development
of Coot</article-title>. <source>Acta Crystallogr., Sect. D: Biol. Crystallogr.</source>
<year>2010</year>, <volume>66</volume>, <fpage>486</fpage>&#x02013;<lpage>501</lpage>. <pub-id pub-id-type="doi">10.1107/S0907444910007493</pub-id>.<pub-id pub-id-type="pmid">20383002</pub-id></mixed-citation></ref><ref id="ref80"><mixed-citation publication-type="journal" id="cit80"><name><surname>Murshudov</surname><given-names>G. N.</given-names></name>; <name><surname>Skubak</surname><given-names>P.</given-names></name>; <name><surname>Lebedev</surname><given-names>A. A.</given-names></name>; <name><surname>Pannu</surname><given-names>N. S.</given-names></name>; <name><surname>Steiner</surname><given-names>R. A.</given-names></name>; <name><surname>Nicholls</surname><given-names>R. A.</given-names></name>; <name><surname>Winn</surname><given-names>M. D.</given-names></name>; <name><surname>Long</surname><given-names>F.</given-names></name>; <name><surname>Vagin</surname><given-names>A. A.</given-names></name>
<article-title>REFMAC5
for the refinement of macromolecular crystal structures</article-title>. <source>Acta Crystallogr., Sect. D: Biol. Crystallogr.</source>
<year>2011</year>, <volume>67</volume>, <fpage>355</fpage>&#x02013;<lpage>367</lpage>. <pub-id pub-id-type="doi">10.1107/S0907444911001314</pub-id>.<pub-id pub-id-type="pmid">21460454</pub-id></mixed-citation></ref><ref id="ref81"><mixed-citation publication-type="journal" id="cit81"><name><surname>Nicholls</surname><given-names>R. A.</given-names></name>; <name><surname>Tykac</surname><given-names>M.</given-names></name>; <name><surname>Kovalevskiy</surname><given-names>O.</given-names></name>; <name><surname>Murshudov</surname><given-names>G. N.</given-names></name>
<article-title>Current
approaches for the fitting and refinement of atomic models into cryo-EM
maps using CCP-EM</article-title>. <source>Acta Crystallogr., Sect.
D: Struct. Biol.</source>
<year>2018</year>, <volume>74</volume>, <fpage>492</fpage>&#x02013;<lpage>505</lpage>. <pub-id pub-id-type="doi">10.1107/S2059798318007313</pub-id>.<pub-id pub-id-type="pmid">29872001</pub-id></mixed-citation></ref><ref id="ref82"><mixed-citation publication-type="journal" id="cit82"><name><surname>Liebschner</surname><given-names>D.</given-names></name>; <name><surname>Afonine</surname><given-names>P. V.</given-names></name>; <name><surname>Baker</surname><given-names>M. L.</given-names></name>; <name><surname>Bunkoczi</surname><given-names>G.</given-names></name>; <name><surname>Chen</surname><given-names>V. B.</given-names></name>; <name><surname>Croll</surname><given-names>T. I.</given-names></name>; <name><surname>Hintze</surname><given-names>B.</given-names></name>; <name><surname>Hung</surname><given-names>L. W.</given-names></name>; <name><surname>Jain</surname><given-names>S.</given-names></name>; <name><surname>McCoy</surname><given-names>A. J.</given-names></name>; <name><surname>Moriarty</surname><given-names>N. W.</given-names></name>; <name><surname>Oeffner</surname><given-names>R. D.</given-names></name>; <name><surname>Poon</surname><given-names>B. K.</given-names></name>; <name><surname>Prisant</surname><given-names>M. G.</given-names></name>; <name><surname>Read</surname><given-names>R. J.</given-names></name>; <name><surname>Richardson</surname><given-names>J. S.</given-names></name>; <name><surname>Richardson</surname><given-names>D. C.</given-names></name>; <name><surname>Sammito</surname><given-names>M. D.</given-names></name>; <name><surname>Sobolev</surname><given-names>O. V.</given-names></name>; <name><surname>Stockwell</surname><given-names>D. H.</given-names></name>; <name><surname>Terwilliger</surname><given-names>T. C.</given-names></name>; <name><surname>Urzhumtsev</surname><given-names>A. G.</given-names></name>; <name><surname>Videau</surname><given-names>L. L.</given-names></name>; <name><surname>Williams</surname><given-names>C. J.</given-names></name>; <name><surname>Adams</surname><given-names>P. D.</given-names></name>
<article-title>Macromolecular structure
determination using X-rays,
neutrons and electrons: recent developments in Phenix</article-title>. <source>Acta Crystallogr., Sect. D: Struct. Biol.</source>
<year>2019</year>, <volume>75</volume>, <fpage>861</fpage>&#x02013;<lpage>877</lpage>. <pub-id pub-id-type="doi">10.1107/S2059798319011471</pub-id>.<pub-id pub-id-type="pmid">31588918</pub-id></mixed-citation></ref></ref-list></back></article>